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ABSTRACT
Vitamin recommendations for 10.., blrth..,eight (LaW) infants
total parenteral nutrition (TPN) are met with J mL of "
multivitllmin supplement, MVI-Pediatric (McGraw Laboratories).
Ho....ever, there is limited data available on the adequacy of
this preparation and on the exact needs of infants receiving
TPN. The purpose of this study was to assess the thiamin,
riboflavin, folate and vitamin Bu status of parenterally fed
LBW infants receiving MVI-Pediatric. Thirty i:1fants were
randomly assigned to raceive either 3 rnL of MVI Pediatric
(PAR3 group; birthweight .. 1133 ± 293 g~ gestational age .=
2!l.4 ± 2.1 weeks) or 2 mL (PAR2 group; 1137 ± 231 g; 28.5 ±
1.8 weeks). One hundred percent ('I received TPN fOI the
first week, 50\ by the second, and less than 3]\ by the third.
Eighteen control infants received enteral feeds only (ENT
group; 1281 ± 271 g; 29.6 ± 1.7 weeks).
Weekly blood, 24 hour urine collections and dietary
intake data ....ere obtained. The adequacy of thiamin anti
riboflavin was assessed by erythrocyte transketoliJse activity
(ETA) and erythrocyte glutathione reductase activity
coefficient (EGRACI respectiVely. Urinary thiamin and
riboflavin levels were measured by fluorometric technigues.
Plasma folate, red blood cell (RBC) folate, urinary folate anti
plasma vitamin 8 12 concentrations were determined by il
radioassay. As well, the thiamin, folate and Bu levels in the
TPN admixture lSnd MVI-Pediatric were analyzed.
The ETA and [GRA were within the nonnal range for all
(il)
groups at each time period. No significant differences were
found in ETA among the J groups. The EGRAC did differ
significantly between the PAR2 (O.9B ± 0.07) and PAR3 groups
(loll ± 0.10) at week 2 but no difference was observed between
the ENT group and the parenteral groups at any time. Urinary
thiamin and riboflavin levels were significantly lower prior
to the initiation of parenteral or enteral feeds than ZIt
subsequent sampling times. However, there was no difference
found between groups during the study period.
No difference was observed in RBC folate levels at any
time. Plasma folate did significantly differ between the PAR3
group (24 ± 7 ng/rnL) and both the PAR2 (13 ± 5 ng/mL) amI ENT
groups (l6 ± J ng/mL) prior to the initiation of feeds and at
week 1 and between the PARJ pO ± 16 ng/mL) and PAR2 (16 ± 4
ng/mL) infants at week 2. A difference was found in plasma
vitamin Sa between the ENT groups (551 ± 287 pg/mL) and both
the parenteral groups (PAR2 = 841 ± 405 pg/mL; PAR3 = 924 ±
424 pg/mL) at week 1 and between the tNT (530 ± 238 pg/mL)
and PAR3 (999 ± 425 pg/mL) groups at week 2.
From the results of the present stUdy it appears that 2
mL of MVI-Pediatric is sufficient to meet the thiamin,
riboflavin, folate and vitamin 812. needs of the parenterally
fed Law infant.
(iii)
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CHAPTER 1.0 INTRODUCTION
Twenty years ago the survival rate of infants weighing
less than 1500 g at birth was 20% (Tsang, 1988). Today 90 -
951 of these infants survive. Improved neonatal intensive
care (e.g. assisted vent.ilation or continuous positive airway
pressure, monitoring of heart rate and respiration, monitoring
of blood gases and intravenou5 feeding) appears to be
responsible for this marked increase in the survival rate
(Halliday et al, 1984).
optimal nutri ticn is critical in the management of the
increasing number of surviving low birthweight (LBW) infants.
Infants' organ growth and development (especially the brain)
depends on adequate nutrition (Brooke, 1987). When the health
of the infant is further compromised by complications such as
surgery, respiratory distress syndroll\e, or the need for
ventilatory assistance, early enteral feeding may not provide
adequate energy and nutrition. However with the development
of total and supplemental parenteral nutrition, the most
vUlnerable infant can receive sufficient nutrients.
Parenteral alimentation can be an effective means of
providing energy and nutrition in the LBW infant who cannot
tolerate enteral feeds. LBW infants given supplemental and
total parenteral nutrition can achieve positive nitrogen
balance and growth rates which parallel the intrauterine
gro....th curve (Chessex and Zebich, 1985; Zlotkin et aI, 1981;
Heird and Winters, 1975). However, after more than a decade
of clinical experience in this field, there is still a lack
of agreement on specific nutrient requirements for the
intravenously fed LBW infant. While protein and othor
nutrient requirements such as copper and zinc of LBW infants
receiving parenteral nutrition have been stUdied extensively
(Zlotkin et aI, 1981: Zlotkin and Buchanan, 1983: Reichman
et aI, 1982), there remains a scarcity of data on the vitamin
requirements of LBW infants receiving parenteral nutrition.
In 1975 the Nutrition Advisory Group of the American
Medical Association established guidel ines for the use of
intravenous vitamins for infants and children up to eleven
years of age [Committee on Nutrition/Nutrition Advisory Group
(CON/NAG), 1979]. These recommendations are based on oral
recommended daily allowances. It has been suggested (Kerner,
1983; Hodges and Dempsey, 1986; Shenkin, 1986) that these
recomllendations be modified for parenteral use for the
following reasons: I) There lIay be nutrient-nutrient
interactions when the vitamin supplement is added to the
parenteral nutrition solution Which nay alter the relative
effectiveness of a specific vitanin; 2) Some vitamins may
adhere to the intravenous tUbing and containers or may undergo
oxidative destruction as observed in the case of vitamin l\
(smith et aI, 1988); 3) Parenteral vitamins are delivered
intravenously rather than enterally which may impair their
activation and/or storage and allow for their rapid excretion
in urine; and, 4) Oral recommendations are designed for the
needs of healthy individuals and do not take into account
special needs or underlying disease states which may alter
nutrient requirements.
The Nutrition Advisory Group (CON/NAG, 1979) suggested
that LBW infants receive 65% of the amount of vitamins
recommended for full term infants. Until recently there were
no published investigations studying the adequacy of the
recommendations for the LBW infant receiving parenteral
nutrition. One complete study and several preliminary reports
have addressed this issue regarding water soluble vitamin
requirements. Moore and collaborators (1986) investigated the
adequacy of MVI-Pediatric (MCGraW Laboratories) ,
multi-vitamin preparation formUlated using the American
Medical Association guidelines, for the LBW infant, term
infant, and children up to eleven years of age who were
receiving short or long term TPN. They observed that the LBW
infant given MVI-Pediatric had high blood levels of ascorbate,
vitamin Bu , folate, niacin and pantothenate. McCoy et al
(1985, abstract) analyzed whole blood B6 levels in human milk,
formUla, and parenterally fed infants. The patients receiving
TPN had high levels of pyridoxal and pyridoxal phosphate.
These investigators concluded that commonly used multivitamin
solutions have excessive amounts of vitamin B6. Manser and
Brodsky (1985, abstract) found that the recommended levels of
folate and Bl2 (50 p,g and 5 IJg, respectively) were excessive
for low birthweight infants. These stUdies implied that there
may be excessive intakes of these vitamins which could be
dangerous to an already high risk group of infants. It has
been suggested (Moore et aI, 1986) that further investigative
work should be done to determine more appropriate dosage
~evels for LBW infants receiving TPN.
Our hypothesis is that pr>;)viding 40% of the amount of
water-soluble vitamin!> recoJ:lmended for full term infants will
maintain normal biochemicd functioning in LBW infants
receiving total parenteral nutrition (TPN). Therefore, the
purpose of this investigar.ion was to determine the adequacy
of 60% (the amount currently used at the Janeway Child Health
Centre, st. John's, Newfoundland) or 40%: of the levels of
thiamin, riboflavin, folate, and vitamin Bu that are
recommended for full term infants for the parenterally fed
LeW infant.
Chapter 2.0 LOW BIR'rHWEIaHT (LBW) INFANTS
DEFINITION OF PREHATURI'I'Y
For a better understanding of the prob~el'l\s associated
with investigating the vitamin requirements of the LBW infant,
insight into the definition of prematurity and factors
affecting the metabolism of vitamins is essentiaL
A preterm infant is any infant who is born prior to 37
week:::: gestation. A LBW infant is born with a weight less than
Z500 g whereas a very low birthweight infant is born weighing
less than 1500 9 (Halliday et aI, 1985). Optimal nutrition
is crucial in the management of LBW infants. Most of the
serious nutritional problems are the result of immaturity,
generally in those infants less than 30 weeks gestation.
Physiological handicaps which may play a role in affecting
nutrient needs and the metabolic handling of vitamins for the
LBW infant are listed in Table 2.1.
PHYSIOLOGICAL HlINDIC1I.PS 1\SSOCIA'l'EO WJ:TH PREM1I.'I'URI'l'Y
LDW infants have diffiCUlty maintaining body temperature
due to an increased heat loss as a result of decreased
subcutaneous fat and a large surface area to body weight
ratio. As a result they are at risk for neonatal cold stress
(Halliday et al, 1985). cold stress is associated with
acidosis and hypolda (stephenson et al, 1970; Gandyet aI,
1964): two factors which impair surfactant production in LBW
infants. In addition the very low birthweight infant has a
TABLE 2.1
PHYSIOLOGICAL HMIDICAPS OF THE LBW INFANT
TEMPERATURE INSTABILITY
RESPIRATORY DIFFICULTIES
GASTROINTESTINAL AND NUTRITIONAL PROBLEMS
HEPATIC IMMATURITY
RENAL IMMATURITY
CEREBP.AL IMMATURITY
IMMUNOLOGICAL DISTURBANCES
CARDIOVASCULAR DISORDERS
greater potential for fluid and electrolyte imbalance cOllpared
to larger LBW infants due to increased insensible water loss
(Sarosohn. 1977). This water loss lIust be controlled to
prevent dehydration nnd hypernatrernia.
Fourteen to twenty per cent of babies born weighing less
than 2500 g (Horley, 1986) develop respiratory distress
syndrolll! (RDS) after birth. Twice as .any .ales are aftected
as females. RDS results from a deficiency of lung surfactant.
During the early management of RDS, infants should not be fed
orally or nasogastricallY for the following reasons; (i)
Infants with RDS often are unable to absorb their feeds
satisfactorily. This increases the likelihood of gastric
distension leading to vomiting and aspiration of milk into the
lungs; (ii) LBW babies have uncoordinated esophageal
peristalsis and easily regurgitate Idlk from their stOllachs
(Harley, 1986); (iii) These infants also have poor laryngeal
protective reflexes that result in it reduced ability to
prevent tracheal aspiration of milk which may lead to a
deterioration in their respiratory condition. consequently,
all infants suffering froll RDS are given parenteral fluids
until their respiratory distress subsides.
Poor sucking and swallowing reflexe.s, especially prior
to 34 weeks gestation, result in oral feeding difficulties
for the LBW infant. Therefore alternate modes of feeding have
been developed to provide total nutrition for these infants.
Nutrient absorption is impaired, espec.tally the digestion
and absorption of fat, calcium, fat-soluble vit.amins, and SOme
of the trace elements. Body levels of calcium, phosphorus,
proteins, vitamins A, C, and E, trace elements and iron are
less than in term infants and deficiencies of these nutrients
may occur with growth (lialliday et aI, 1985).
The pathways of intermediary metabolism of several amino
acids in the liver of the LBW infant are incomplete or
function inadequately. for example, the last enzyme in the
transsulfuration pathway, cystathionase, is absent or reduced
in the fetal liver and it appears only slOWly after birth in
LBW infants (Brooke, 1987). Therefore, the synthesis of
cysteine is reduced causing this amino acid to be considered
essential for this group. The absence of cystathionase also
limits the tolerance to methionine which would normally be
converted to cysteine if given in excess (Komrower and Robins,
1969) . LBW infants fed high protein diets are more
susceptible to hypermethioninemia which may result in
neurological disturbances (Komrower and Robins, 1969).
Impaired conjugation and excretion of bilirubin results
in hyperbilirubinemia which may lead to physiologic jaundice.
Phototherapy is effective in reducing the serum unconjugated
bilirubin concentration in newborns (cremer et aI, 1958;
r.ucey, 1972). One complication of phototherapy is the
possible degradation of riboflavin (Sisson, 1987; Bates et
301. 1985).
The immature brain is vulnerable, as ....ell, to toxic
effects of raised concentrations of certain amino acids such
as phenylalanine, methionine, histidine, and the branched
chain amino acids (Brooke, 1987).
Due to renal immaturity, LaW infants have difficulties in
excreting large solute loads and thus, a relatively dilute
urine is produced. "Late metabolic acidosis" may develop froll
a disproportion bet....een the daily load of nonvolatile acid
generated in the body and the kidneys' ability to excrete it
(Tuck, 1986). A 10.... renal threshold for glucose results in
persisent glycosuria in spite of normal blood sugar
concentrations in some LBW infants. This limits glucose
intake in intravenous feeding and may cause osmotic polyuria
with disturbance of water balance (Brooke, 1987).
LBW infants have a reduced ability to combat infection due
to the absence of placental transmission of immunoglobulins
(IgM,IgA), relative inability to produce antibodies, impaired
phagocytosis and decreased inflammatory response (Halliday et
aI, 1985). Infection frequently results in apnea, lethargy,
gastrointestinal distention, vomiting, acidosis, and
hypotension (Sarasohn, 1977).
The LeW infant is also at risk for persistent ductus
arteriosus (PDA). The incidence of PO" in LaW infants is
between 7 and 35\ for all neonates weighing less than 1500 9
(Levin at aI, 1975; Rowe at aI, 1981)_ Tha ductus arteriosus
is a blood vessel which allows blood to bypass the lungs
during intrauterine life. The physiological closure of this
vessel usually occurs 24 hours after birth for a full term
infant but may remain open in the preterm infant. The failure
of the ductus to close nonally may be due to a combination
of hypoxia (often as a result of ROS) and immaturity
(Wilkinson and cooke, 1986).
2.3 METHODS OF FEEDING
There is no general agreement about the idelol method to
provide feedings for LBW infants. The method chosen depends
upon the gestational age, birthweight, and clinical condition
of the infant. The feeding of LBW infants is usually done in
two phases I 1) the first phase is a period of instabil i ty
and illness in which intragastric feeds are not tolerated and
the provision of fluids and nutrients intravenously is
necessary, and 2) the period of rapid growth during which
enteral feeds are better tolerated.
PARENTERAL NUTRITION
Total parenteral nutrition (TPN) is used to maintain
adequate nutrition and a positive nitrogen balance by the
intravenous administration of most essential nutrients
required by the body. LBW infants with severe respiratory
disease, congenital anomalies of the gastrointestinal tract
or inflammatory disease of the intestinal mucosa (i. e.
necrotizing enterocolitis) are candidates for this mode o[
support.
The earliest reported use of intravenous feedings for
neonates was during the 1930'S (Pereira and Glassman, 1983).
The peripheral intravenous infusion of protein (casein),
protein hydrolysates, homogenized oils and lecithin emUlsions,
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and dextrose into severely malnourished infants for several
days achieved positive nitrogen balance and weight gain. In
1966 oudrick developed a more refined mixture of dextrose and
amino acids that was administered through a central venous
catheter that also resulted in normal growth and development
in infants. Intravenous fat emulsions along with vitamin
formulations were added to parenteral solutions in the 1970's
and more recently trace minerals were included.
positive nitrogen balance has been observed in LBW infants
with parenteral lipid and/or glucose energy intakes of 60
kcal/kg/d and amino acid infusions of 2.5-3.0 g/kg/d (Anderson
et ai, 1979). It appears that growth requires a minimal
parenteral nonprotein energy intake of 70 kcal/kg/d. Problems
arise if glucose is used as the sole nonprotein energy
source. At glucose concentrations greater than 13 9/dL there
appears to be local irritation of peripheral veins resulting
in tissue necrosis (Cowett et aI, 1979). LBW infants also
have poor glucose tolerance during their first few days of
life with hyperglycemia appearing frequently at infusion rates
greater than 6 mg/kg/lIlin (Dweck and Cassady, 1974). Thus, it
is recommended that glucose infusions begin at 6 mg/kg/min for
infants weighing less than 1000 g and infusions not exceeding
8 mg/kg/lIlin for those weighing between 1000 - 1500 g
(Lifschitz, 1988).
There are three advantages in providing intravenous lipid
preparations to LBW infants; 1) it is a sc~rce of essential
fatty acidS, 2) it has a high caloric density, and 3) its low
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osmolality makes it suitable for perip;'teral vein use.
However, Law infants have a decreased ability to clear both
free fatty acids and triglycerides from their serum. This
impaired clearance of triglycerides may be secondary to a
decreased activity of lipoprotein lipase resulting from
reduced adipose tissue mass or hepatic immaturity (Pereira and
Glassman, 1983).
The nitrogen in parenteral solutions is usually provided
as a mixture of crystalline amino acids. It has been shown
that the nitrogen of amino acid mixtures is utilized better
than the nitrogen of protein hydrolysates (Duffy et aI, 1981).
Inadequate provision of amino acids is associated with failure
to thrive, hypoalbuminemia and edema. Excessive amino acid
intake can lead to hyperammonemia, metabolic acidosis, nnd
possiblY cholestatic jaundice ('iu, 19861 Pereira and
Glassman, 1983).
Suggested daily intakes of minerals and vitamins are
presented in Table 2.2. The justification for the use of TPN
has been established in terms of energy and growth
requirements for the LBW infant but little is known of the
requirements and utilization of micronutrients.
The single most problematic gastrointestinal compl ication
of TPN is liver disease which presents clinically as jaundice,
and histologically as cholestasis (pereira et al, 1981).
Although one·third of LBW infants receiving TPN develop
elevated liver function tests indicative of liver disease, the
etiology remains obscure.
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TABLE 2.2
SUGGESTED DAILY :INTAKES OF VITAMINS. AND TRACE MINERALS+
FOR LBW INFANTS RECEIVING TPN
Nutrient
Zn (jt<.l)
CU (#g)
!lJg)
vitamin A (IU)
Vitamin D (lU)
Vitamin E (IU)
Vitamin K (,:.Ig)
Thiamin (mg)
Riboflavin (mg)
Niucin (rog)
Panthothenic Acid (mg)
Pyridoxine (mg)
vi tilmin C (nlg)
Folate (/l9)
vitamin Bl~ (J'g)
Iliotin (J'9)
Recommended Amount
unit dose/kg/d
300
200
704**
2-10
unit dose/d
13BO
240
4.2
0.12
0.72
0.84
10.2
0.6
48
84
0.6
12
*'l'ho:,;o levels are recommended on the manufacturers' product insert
of ~lVI-Pedi<ltric in Canada. However, the American Medical
Association revised their recommendation in 1988.
+CON/A~IA, 1985.
**,T;lmes at 31., 1975.
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2.3.2 GASTRIC ENTERAL FEEDING
Aggressive intravenous feedings should not preclude
enteral feeding since even small amounts can stimulate
gastrointestinal enzymatic development and activity, promote
bile flow and increase small intestinal villoUS growth (¥u,
1987) •
The method of .?roviding bolus feeding into the stomach at
frequent interval.; (1 to 4 hours) has been commonly used in
neonates for decades. Bolus feedings, however, may not be
well tolerated by infants with delayed gastric emptying or
respiratory problems. Pitcher-Wilmott and coworkers (l!l7!l)
demonstrated a transient decrease in arterial oxygen tension
and lung volumes in LBW infants recovering from respiratory
distress who were receiving bolus feedings. continuous
gastric feedings may be tolerated better than intermittent
gavage feedings especially if gastric emptying is not limiting
in the infant (Landwith, 1972; Parker, 19B1).
In 1970, Rhea and Kilby described a new teChnique in which
feedings were delivered continuously by a tube passed either
orally or nasally and advanCed through the pylorus into the
distal duodenum or jejunum. However, there have been
criticisms of the transpyloric mode of feeding. The
campI ications associated with transpyloric feeding include;
1) bacterial overgrowth of the upper intestine (Challacombc,
1974), 2) decreased absorption of potassium and fat (Roy et
aI, 1977), and 3) dumping syndrome and diarrhea (Hcird,
1974). Controlled studies failed to demonstrate advantages
of using the transpyloric method of feeding over nasogastric
techniques (Pereira and Lemons, 1981).
The American Academy of Pediatrics (1985) recommended
intermittent gavage feedings as the method of choice for low
birthweight infants but transpyloric and continuous gastric
feedings could be considered for cases of extreme prematurity,
ROS, delayed gastric emptying time and severe gastroesophageal
reflux.
2.3.3 TYPES OF MILK AVAILABLE FOR ENTERAL FEEDING
2.3.3.1 HUMJ\N MILK
The nutritional adequacy of human milk for LBW infants is
not as well established as it is for full term neonates.
Pooled human milk was the preferred mode of feeding for LBW
infants until the 1940's. StUdies have shown, however, that
peoled human milk from mothers of term infants does not meet
all the nutritional requirements of LBW infants and results
in a slower rate of growth than is found with the intake of
their mother1s own milk or commercial formulas. Fomon et al
(1977) and Davies et al (1977) have suggested that banked
human milk is not appropriate for LBW infants due to less than
satisfactory concentrations of protein, minerals, and
calories.
The milk of mothers of preterm infants (PTM) is
qualitatively different from the milk of mothers of full term
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babies (FTM). Since 1978 there has been a series of papers
describing the differences in composition of PTM and FTM
(Atkinson, 1978, 1980, 1981; Lemons, 1982; Gross, 1980)
(Table 2.3). There are differing opinions regarding the
relative concentrations of lactose, fat, calories and sodium.
Atkinson at al (1978, 1980, 1981) reported that during the
first month of lactation there was higher nitrogen, fat, and
caloric content in Pl'M than FTM and lower concentrat:lons of
lactose. However, sodium, chloride, calcium, phosphate,
potassium, and magnesium levels were similar in both milks.
Lemons and coworkers (1982) found significantly greatar
protein, sodium, chloride, magnesium, and iron levels in PTM
whereas lactose, fat and energy concentrations were similar.
Protein and nonprotein nitrogen have consistently been found
higher in PTM.
The water-solUble vitamin content of human milk is readily
influenced by maternal diet. Ascorbic acid, nicotinic acid,
riboflavin, thiamin, pantothenic acid, vi.tamins Bn and fiG are
all relatively responsive to the recent maternal diet (Ford,
1983). In contrast, the fat-soluble vitamin content of milk
appears to reflect both maternal vitamin stores arising from
past diet intake as well as current diet (Anderson, 1985).
LBW infants fed PTM during the first month of life exhibit
growth rates similar to those of infants fed whey protein
formula and demonstrate positive retention rates of nitrogen,
sodium, potassium, and chloride (Anderson, 1985; Pereira and
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'l'ABLE 2.3
COHPOSITION OF PTH AND FTH DURING THE FIRST MONTH OF LACTATION-
DAYS OF LACTATION
3-5 8-11 Mature
NUTRIENTS
(units) FTM PTM FTM PTM FTM PTM
Energy 48;t9 S8!:."' 59;t6 71;t8 62;t2 70±9
(kcal/dLI
Protein 1. 87;t0. 18 2.10;t0.23 1.70±0.18 1. 86±0.19 1. 29±0. 09 1.41±0.08
(9/dL)
Lactose S.14;t0.70 5.04±0.43 5. 98!.0.73 S.SS±0.35 6. 51±0. S6 5.g7±0.35 ::;
(9/dL)
ClI (IlKJ/L) 0.72±0.13 0.83±0.21 O. 73±0. 21 0.78±0.18 0.58±0.09 0,63±0.14
Fe (mg/L) 1. 11±0. 43 1.10±0.34 0.99:0.31 0.99±0.27 0.88±0.28 0.90;tO.23
Zn (mg/L) 5.35±1.20 S.30±!.45 4.10±0.65 4.75±1,56 2.60;!:.0.65 3.92±1.10
Net (gIL) 0.43±0.09 0.53±0.20 O.32:!:.0.12 0.46±0.14 0.25±0.09 0.28tO.10
Cl (gIL) 0. 821°.02 0.84.!.O.29 0.64±0,19 0.78±0.19 0.46±0.11 0.46±0.16
K (gIL) O.72;tO.ll 0.72±0.09 0.63;tO.09 0.68±0.11 O.S7±O.09 0.S7±O.07
Ca (gIL) O.32;t0.04 0.33;tO.09 0.29±0.03 O.30±0.lO 0.26±0.05 O.28:!:.0.04
P (gIL) O.12;t0.05 0.14±0.05 0. 15:!:.0. 03 O.IS±0.04 0.13±0.01 0.15±0.O4
TABLE: 2.3 {CONT'D}
Mg (rng/L) 29.90:t4 99 n.00z5.30 27. 70z2. 70 34. 00Z7. a 29.45;t2.90 34.JO;t5.10
Carotene 117±-35 U7;t35 20::!:17 31;t22
(,ug/dL)
Retinol 200::!:40 163;t40 87:t21 121:t29
ester (,ug/dL)
**Riboflavin 28.8 27.6 27.9 36.0 31.0 26.6
(,ug/dL)
uThiamin 2.84 2.37 6.46 5.40 18.30 8.93
(,ug/dL)
**Vitarnin B6 1.70 loll 3.49 2.58
(,u9/dL)
·*Vitamin BIZ 0.05 0.09 O.OJ 0.05 0.02 0.02 ~(,ug/dL)
**Folic acid 1. 76 1.06 J.12 2.09 4.23 3.05
(,ug/dL)
*Adapted from Anderson (1985).
**Means but no standard deviation 'Were available.
Barbosa, 1986). However, the concentrations of calcium,
phosphorus, sodium, iron, copper, and zinc in PTK are still
considered insufficient for this group (Mendelson et aI, 1983 i
Pereira and Barbosa, 1986).
The anti-infection qualities of human milk are important
attributes when considering desirable feeding choices for LBW
infants. Gross (1981) observed that PTM contained higher
amounts at IgA than FTM. Secretory IqA inhibits the adherence
and proliferation of bacteria at epithelial surfaces and is
important in controlling the microbial environment of the
intestinal tract.
It is clear that PTM has advantages (i.e. greater nutrient
density, immunologic properties and easier digestibility) over
FTM as well ao formula, at least during the first month of
life of LBW infants.
COMMERCIALLY PREPARED FORMULA
II.s an alternative to human milk, proprietary formulas are
complete foods requiring no supplementation. Results of
feeding and growth studies led to the development of
commercial formulas for LeW infants (American Academy of
Pediatrics, 1977). The common features of these formulas
include Whey-predominant protein, carbohydrate mixtures of
lactose and glucose polymers and fat mixtures containing
combinations of medium chain triglycerides (MeT).
comparison of the nutritional content of these formulas is
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shown in Table 2.4. The vitali in levels in the fortllulas aro
equal to or higher than those found in human milk. The
stability of some of the vitamins is limited and a !';ubstantial
reduction of biological activity Ilay occur following heat
treatment, canning, or light exposure (Orzalesi, 1987).
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n.BLE 2.4
NUTRIENT COMPOSITION OF PROPRIETARY INFANT FORMULAS FOR LOW
BIRTHWEIGHT INFANTS
Component Enfamil SMA Similac
premature "preemie" special
Care
Protein (g/dL) 2.4 2.0 2.2
Whey casein ratio 60:40 60:40 60:40
Fat (g/dL) 4.' 4.4 4.4
MCT 40' '2% 50'
Oleo oil
°
'0'
°Corn oil 40'
°
JO'
(.1leic oil
°
'5%
°Coconut oil
'0' 25% '0'
Soy oil
°
'8%
°
Carbohydrate (g/dL) B.9 B.6 6.6
Lactose 40' 50' 50'
Glucose polymers 60' 50% 50'
Minerals
CalciulII (mg/dL) 95 75 144
Phosphorus (mg/dL) 4B 40 72
Sodium (mg/dL) J2 J2 J5
Potassium (mg/dL) 90 75 100
Chloride (mg/dL) 69 53 65
Magnesium (mg/dL) B 7 '0
Zinc (mg/dL) O.B 0.5 1.'
Copper (mg/dL) 0.073 0.070 0.'
Manganese (mg/dL) 0.021 0.020 0.020
Iron (mg/dL) 0.13 O.J O.J
Iodine (mg/dL) 0.006 0.008 0.015
Vitamins
A (lU/L) 2540 3200 5500
°
(Ili/L) 507 510 1200
E (lU/L) 16 15 JO
C (mg/L) 69 70 JOO
B, (mg/L) 0.63 O.B 2
B, (mg/L) 0.74 1.J 5
Niacin (mg/L) 10.1 6.J 40
B, (mg/L) 0.53 0.5 2
Bu (~g/L) 2.5 , 4.5
Folic acid (~g/L) 240 '00 JOO
K (mg/L) 0.08 0.07 0.'
Cal/dL 8' B' 81
"
CHAPTER 3.0 VI'Z'1\MIN METABOLISM IN HUMANS
3 • 1. INTRODUCTION
vitamins are essential for the growing infant. Presently
recommendations for the heal thy full term infant are based on
vitamin intakes from human milk (Committee on Nutrition,
American Academy of Pediatrics, 1976). For the LBW infant a
safety factor is added to these recommendations (Tsang, 1988).
However, the assumption that the LBW infant needs will be met
with adjustments for energy intake or body weight is no longer
considered valid. LBW infants may be more vulnerable to
develop vitamin deficiencies than full term infants because
of predisposing factors such as lower body stores, decreased
availability or intake, decreased absorption and an increased
need utilization (analesi and Colarizi, 1982).
Furthermore, the effects of excess vitamin administration for
therapeutic reasons in LBW infants are unknown.
Whether nutrients are given by enteral or parenteral
routes can also affect vitamin requirements. Guidelines for
the intravenous use of vitamins are based on oral requirements
(American Medical Association, 1979). However, parenteral
requirements for vitamins may be quantitatively different from
oral requirements for reasons already mentioned (Chapter 1.0).
Moore et a1 (1986) addressed the appropriateness of the
present recommended intravenous intake of certain water
soluble vitamins. They determined serum levels of water
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soluble vitamins and certain functional indices of vitamin
status in infants and children, including 18 LBW infants,
receiving an intravenous multivitamin preparation (MVI-
Pediatric). While there was no matched enterally fed group,
nor premature cord blood samples, the serum levels of most
water soluble vitamins in LBW infants did exceed several-fold
that of term infants and older children. Assays to determine
the adequacy of thiamin, riboflavin, and pyridoxine, were
conducted and it was found that there was no apparent
deficiency at the recommended levels of intake. In a
preliminary study, Manser and Brodsky (abstract, 1985)
indicated that vitamin BIz and folate at intravenous intakes
of 5 /1g/d and 50 /1g/d, respectively, resulted in apparent
excessive levels of both vitamins. Greene and coworkers
(abstract, 1988) evaluated the plasma and red cell riboflavin
levels as well as flavin adenine dinucleotide (FAD)
concentrations in infants less than 1. 5 kg who received TPN
for the first 3-4 weeks of life. Their study indicated that
plasma riboflavin levels increased 40-100 fold with the
currently recommended dose of riboflavin and stated that a
reduced renal clearance as well as an excessive intake were
important determinants of this phenomenon.
3.2 THIAMIN METABOLISM
Thiamin (Figure 3.1) is important as an constituent in
many of coenzymes of carbohydrate and amino acid )netabolislll.
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The most abundant form of thiamin in animal tissues is thi ..min
pyrophosphate (TPP), a coenzyme which plays an integral part
of two general enzymatic sequences; 1) decarboxylation or
a-keto<!lcids and; 2) transketolation in the pentose phosphate
pathway yielding NADPH and ribose from the metabolism or
glucose (Marks, 1985).
In the Kreb's cycle two thiamin dependent reactions occur.
Pyruvic acid is converted to acetyl eoA through the action or
Pigure 3.1
Structure of Thiamin Hel
..e,
~. NIH. S
CH .... ,' , ~c' ~.' , ~~ - CH.CH,OH
N' ,~ '/I('---'CH
.. , ."... , I '
C CH, 0 CH,
pyruvate dehydrogenase in association with coenzyme A and
lipoic acid. The conversion of a-ketoglutarate to "active
succinyl semi-aldehyde" is catalyzed by a-ketoglutarate
dehydrogenase which, through the participation with lipoic
acid and coenzyme A, yields succinyl coenzyme A.
Transketolase catalyzes two reactions in the pcnto!>c
phosphate pathway. The ketol groups of appropriate
keto-sugars form an active glycoaldehyde-cnzyme intermediate
with TPP which is then transferred to a suitable acceptor
aldehyde. consequently, transketolase is capable of
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functioning in a number of donor-acceptor systems. However,
the main action of this enzyme is related to
ribulose-5-phosphate metabolism yielding ribose for nucleotide
formation (Mock, 1986; Sauberlich, 1967).
Thiamin is rapidly and actively absorbed by the small
intC!stine and is then, intracellularly phosphorylated to the
active coenzyme, TPP. Rindi and coworkers (1972) observed
that the human jejunal mucosa absorbs thiamin at low
concentrations by an active, carrier-mediated process that can
accumulate thiamin against a concentration gradient. In fact,
two transport systems have been demonstrated in the intestinal
1) passive diffusion at thiamin concentrations
greater than #M, and 2) an active saturable
sodium-dependent process at concentrations less than 2 #M
(Komai et aI, 1974). Factors such as anoxia, sodium
deficiency, low temperatures and excessive alcohol consumption
decrease thiamin absorption (Gluber, 1984). Thiamin
preparations with greater lipid solubility (Le. thiamin alkyl
disulphides) are much more readily absorbed and thUs, result
in higher blood and tissue levels than found with preparations
containing thiamin hydrochloride (Gluber, 1984).
The body is incapable of storing free thiamin but small
amounts of the phosphorylated form are present in all cells.
In fact, most nonlipid tissues contain approximately 1 f..I.9
thiamin/g tissue (Greene, 1981). Whole blood has been
reported to contain 5-8 #9/100 mL in adults. Levels less than
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4 119/100 mL are an indication of a thiamin deficiency.
Henshaw and associates (1970) found erythrocytes to contain
22.5 ± 5.88 119/100 mL in a group of college women. However,
blood thiamin may not be useful in detecting thiamin
deficiency for the following reasons; (i) there is usually
only a small reduction in blood thiamin during deficiency
states, (ii) there are technical difficUlties associated with
its measurement, and (iii) whole blood thiamin concentrations
are a reflection of the immediately preceding intake and may
not be a reliable index of tissue stores, distribution, or
actual biochemical functio:ling. Thus, the level of blood
thiamin may be of limited value for the interpretation of
actual thiamin status (Sauberlich et aI, 1974).
Excess dietary thiamin leads to an increase in urinary
thiamin output. The determination of daily urinary thiamin
excretion has been used to estimate thiamin status but these
values only reflect recent intake and not body stores.
urinary thiamin decreases proportionately to thiamin intake
to a threshold point after which further lowering of intake
resul ts in only minor and variable changes in urinary
excretion. Intakes of thiamin less than the threshold
critical point will cause depletion of tissue stores of the
vitamin and could result in symptoms of deficiency (Sauber!ich
et aI, 1974). If an adult consumes 0.5 rng/IOOO kcal/d, 100
119 of thiamin is excreted in the urine. If the intake is
lowered to 0.36 mg/IOOO kca1/d, then the output is reduced to
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40-50 1'9 (Sauberlich ct al, 1974). Knowledge concerning
urinary excretion levels in children is limited but output
levels of 40-100 ~g/d or 176 j.lg/g creatinine have been
reported (Greene, 1981). stearns et al (1958) concluded that
children consuming 0.5 mg of thiamin or less excreted about
lOt of their daily intake. At intake levels above this, the
mean output value was approximately 20%. A deficiency likely
exhts in children if urinary thiamin output is less than 15
11-g/24 h or less than 120 119/9 creatinine (Greene, 1981).
More than twenty thiamin metabolites have been found in
human urine. Of these, eight appear to be major (Sauberlich,
1967). None have been proven useful thus far for evaluating
thiamin status. However, additional studies may reveal that
the amount of thiamin metabolites excreted may represent a
measure of th£'. rate at ....hich body stores of thiamin
depleted.
A dietary lack or inability to assimilate thiamin
result in the deficiency disorder, beriberi. Beriberi has a
spectrum of manifestations ranging from severe cardiac failure
in 'wet beriberi' to a variety of neurologic deficits in 'dry
beriberi'. The commonly observed symptoms include general
malaise, headache, nausea, generalized achin9 of muscles,
vomiting, fatigue, anorexia and psychic and emotional
disturbances such as irritability, moodiness, depression
(Sauberlich, 1967). Neurologic symptoms of beriberi may not
occur for several months after tissue levels of thiamin are
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deficient because of the slo... degeneration of affected nervous
tissue. Reactions involving decarboxylation of a-kotbacids
are .ore affected and accumulation of pyruvate, lactatc!,
a-ketoglutarate, and glutamate occur in the serum and urine
before neurologic symptoms develop (Greene, 1981).
condition called infantile beriberi haa been observed in
breast-fed infants predominantly in rice-consu_ing countries.
These infants present with generalized edema, dyspnea,
anorexia, vomiting, cardiac disturbances, 01 iguria, and
aphonia or 'beriberi cry' (Sauberlich, 1967).
It is important to note that the metabolism and function
of thiamin may be modified by changes in the levels of other
nutrients. For instance, a rise in carbohydrate intake
increases the requirement for thiamin whereas the requirement
decreases when fat consumption is increased. Disturbances in
thia.in function and a reduction in thiamin levels in tissues
results from a decrease in magnesium, pyridoxine, and vitamin
Bl~' Folate deficiency leads to thiamin malabsorption.
Thiallin deficiency can also be caused by chronic alcoholism
(Clark et aI, 1984).
In humans, no toxic effects of thiamin have been reported.
However, anaphylaxis secondary to parenteral use has boen
observed but thiamin intakes of 100 mq or less are rarely
associated with anaphylactic reaction (Aldaheff et aI, 1984).
Based on nutrition surveys and experimental deficiencies,
the adult requirement for thi'lmin has been estimated to be
2.
0.2-0.23 mg/1000 kcal (Gluber, 1984). with the addition of
a safety factor, 0.4 mg/lOOO kcal appears to be adequate for
most healthy adults (Health and Welfare Canada, 1983).
For infants there is little data available on thiamin
needs even though thiamin is involved in neurological
function, an area of great concern in the developL,g child.
The suggested recommended oral intake for infants is 0.4
mg/1000 kcal (Health and Welfare Canada, 1983). This is
higher than the level secreted in breast milk by well
nourished mothers. Since the thiamin intake of breastfed
infilnts appears satisfactory (0.3 mq/1000 kcal) , the amount
recommended should supply the basic need and an added safety
factor.
3.3 RIBOFLAVIN METABOLISM
Riboflavin (Figure J. 2) is a yellow-green, fluorescent,
water soluble pigment widely distributed in plant and animal
cells (Shah, 1985; Marks, 1985; Mock, 1986). This vitamin
is incorporated into two active coenzymes, flavin adenine
dinucleotide (FAD) and flavin mononucleoti.de (FMN) (Figure
J. J) which form the prosthetic groups of many different enzyme
systems (flavoproteins) involved in the oxidative degradation
of pyruvate, fatty acids and amino acids, electron transport
and in drug metabolism. Flavoproteins are relatively unstable
especially when tissue protein is depleted by physiologic
stress, dietary deficiency, or disease.
2.
Under these
conditions increased levels of riboflavin are ~xcreted in the
urine (Greene, 1981).
Figure 3.2
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Riboflavin is absorbed in the small intestine by a
site-specific, saturable, specialized transport process. The
absoqltion of free riboflavin and FMN have been studied in
both humans and rats (Marks, 1985; Greene, 1981). FMN is
hydrolyzed in the upper gastrointestinal tract to free
riboflavin which then enters the mucosal cells of the small
intestine. Riboflavin is then phosphorylated to FMN which
enters the portal system where it is bound to albumin,
transported to the liver, and converted to FAD.
In human plasma, about one half of free riboflavin and 80%
of FMN is bound to protein, primarily albumin. Spector (1980)
observed that certain drugs (i.e. ouabain, theophylline, and
penicillin) may displace riboflavin from the binding protein
and therefore inhibit transport to the central nervous system.
Riboflavin is present in all cells only as functioning
compounds and not as stored material, although the liver (with
16 ~g/g tissue) and kidney (With 25 1l9/9 tissue) usuall.y
contain more than the other tissues which average about 2.3
/Jg/g (Greene, 1981). Burch et al (1948) found the erythrocyte
riboflavin content to be 20.2-27.6 ~g/100 mL cells in
supplemented SUbjects and 10.0-13.1 Ilg/100 mL in deficient
subjects. In the various tissues, riboflavin is usually
present as a phosphate or one of the coenzymes. In the retina,
however, riboflavin is present in the free form, the
significance being unknown (Marks, 1985).
Small quantities of this vitamin are lost in sweat and
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excess amounts are eliminated in the urine. Studies of the
turnover rate of ribof~avin in the normal state have shown
that the half life is about 16 days. Riboflavin has been
thought to be excreted unchanged since no decomposition
product has been found in the tissues or urine (Cooperman and
Lopez, 1984).
Since the body metabolizes little riboflavin urinary
excretion appears to correlate well with reserves and intake
of the vitamin. When body stores in adults are saturated a
daily intuke of 1.3 mg results in almost quantitative
excretion in urine. When body stores are depleted or when the
daily intake is less than I mg, urinary excretion is reduced
(Selhub and Rosenberg, 1984). urinary output changes with age
and pregnancy. In conditions of negative nitrogen balance,
fasting, enforced bed rest, and heat stress, increased
eKcretion levels havo been observed whereas sleep and short
periods of heavy physical work decrease riboflavin excretion
(Sauberlich et aI, 1974).
Isolated riboflavin deficiency is rare. It is common in
association with pellegra, beriberi, and kwashiorkor (Selhub
and Rosenberg, 1984). Clinical features of deficiency are
photophobia, a burning ocular sensation, dim vision, and sore
mouth and tongue. Nonspecific symptoms of anorexia, weight
loss, weakness, headache, dizziness, and confusion may precede
overt symptoms of stomatitis, pharyngitis, glossitis,
seborrhoeic dermatitis, normochromic normocytic anemia and
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corneal vaSCUlarization. In infants and children, dip.tary
deficiency, which is most common in the spring and summer
months, may lead to symptoms within one to two months (Greene,
1981) •
Riboflavin deficiencY may occur from a decrease in intake,
malabsorption, or an increase in need especially during
pregnancy, periods of rapid growth, acute or chronic
infection, and trauma. Absorption of riboflavin is reduced
in hepatitis, cirrhosis, and probenecid treatment (Greene,
1981) .
Riboflavin toxicity has not been reported in animals or
man. There may be interactions with drugs or other vitamins
(Greene, 1981: Mock, 1966; Aldahef.l'" et aI, 1984). For
instance, riboflavin may inhibit the uptake of methotrexate
by neoplastic cells.
The minimum recommended intake for adults to maintain
normal riboflavin output is 0.5 mg/lOOO keal (Health and
Welfare Canada, 1983). Very little infonnation is available
on the riboflavin requirements of infants and children.
lIeal th and Welfare Canada (1983) recommend that infants should
receive an oral intake of 0.5 mg/1000 kcal. Factors that
influence riboflavin status and hence requirements inclUde
drugs, disease (Le. thyroid and congenital heart disease),
phototherapy, age, and other nutrients.
Ingestion of boric acid, probenecid, and oral
contraceptive drugs may induce riboflavin deficiency. Boric
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acid displaces riboflavin from plasma binding sites and
results in increased urinary excretion of the vitamin (Roe et
aI, 1972) whereas probeneciu inhibits gastrointestinal
absorption and renal tubular secretion of riboflavin.
Anticholinergic drugs delay gastric emptyinq and decrease
intestinal transit rate allowing for an increase in riboflavin
absorption (Jusko and Levy, 1975).
Thyroid disease affects riboflavin metabolism. Thyroxine
stimulates intestinal motility and as a result riboflavin
absorption is decreased in hyperthyroidism and increased in
hypothyroidism (Rivlin, 1970a). Rivlin (1970b) has also
reported that flavokinase actiVity is suppressed in
hypothyroidism and liver levels of FAD and FMN are depressed.
Since thyroid function in these infants could be immature then
the possibility of an increased requirement must be
considered. A high prevalence of riboflavin deficiency has
been observed in children due to congenital heart disease
(Steier et aI, 1976). This condition is associated with
deficiencies of other vitamins as well.
Treatment modalities for special conditions can affect
vitamin requirements for the full term and LBW infant.
Phototherapy, the treatment for neonatal hyperbilirubinemia,
may also result in the photodegradation of ribof~avin (sisson,
1.987: Bates et aI, 1985). Riboflavin is especially sp.nsitive
to blue light (the light used for phototherapy) since its
excitation maximum is at 450 nm. Thus the combinlltfon of low
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body stores, low intakes, and phototherapy may result in a
deficiency of riboflavin at a critical period for the newborn.
Bates and coworkers (1985) examined the susceptibility of
riboflavin anci vitamin A in l)".:east milk to photodegradatlon
by exposing the milk to daylight and to phototherapy
illumination under conditions similar to those encountered in
the neonatal unit. They found up to SOt of riboflavin was
destroyed when human breast milk was exposed to daylight or
photo·therapy either in translucent pol}thene bottles or where
milk was pumped through nasogastric tubing from a syringe to
mimic the conditions of enteral feeding. Smith et al (1988)
investigated the effect of phototherapy light on the vitamin
stabi 1 ity in TPN admixtures and found that there were
significant decreases in the amount of riboflavin remaining
after 48 hours. These losses were about the same for all the
amino acid solutions used and in both plastic bags and glass
flasks. The light-induced destruction of riboflavin tended
to not be as great when Intralipid was included in the
admixtures.
Is it the riboflavin in the body tissues Which is
destroyed by phototherapy or does light destroy the vitamin
in the TPN solution? Clearly, it has been shown that light
degrades the vitamin in the TPN admixture (Bates et aI, 1985;
Smith et aI, 19S8). However, in studies done on rats exposed
to the sun for 20 hours during a course of 13 days, a
significant decrease in total flavin concentration was
J5
obsarved in blood (25% decrease), kidneys (40% decrease) and
liver (60% decrease) while urinary excretion was increased
(Maslenikova, 1963).
The use of phototherapy has been reported (Hovi et aI,
1979) to produce a biochemical riboflavin deficiency in breast
fed newborn infants as measured by the activation of
erythrocyte glutathione reductase. Hovi et al (1979) studied
65 newborns; 28 healthy newborns and 37 newborns with
hyperbilirubinemia prior to and during phototherapy. Their
data indicated that healthy newborns given human milk which
is relatively poor in riboflavin, had evidence of transient
riboflavin depletion after birth. This effect was made more
pronounced by phototherapy and was partially prevented by
parenteral or oral administration of moderate amounts of
riboflavin. Meloni and coworkers (1982), on the other hand,
observed that phototherapy did not influence riboflavin status
in nomal or glucose-6-phosphate dehydrogenase deficient
infants SUffering from neonatal jaundice. The discrepancies
in the studies could be due to the fact that infants observed
by Meloni were exposed to phototherapy for less than 48 hours
as opposed to the average of 3 days as in other investigations
and these infants were formula fed as opposed to breast fed.
Other factors to consider are the variability of maternal
riboflavin intake and thus fetal stores at birth, differences
in postnatal sampling ages, slight differences in laboratory
methods for analyzing erythrocyte glutathione reductase
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activation, feeding practisos and vitamin supplementation.
It was recently shown (Lucas and Bates, ],984) that
biochemical riboflavin deficiency if'; common in LBW infants.
Lucas and Bates (1984) investigated the riboflavin status of
68 LBW infants receiving banked human milk (0.3 mg
riboflavin/L) or being fed formu].a containing 1. 8 mg
riboflavin/L. Riboflavin status was determined by the
erythrocyte glutathione reductase activity using an activity
coeffici.ent (Ae) equal to 1.3 as the upper limit of normality.
They concluded that the two factors which were associated with
the biochemical evidence of impaired riboflavin status wer~
the relatively late introduction of the multivitamin
supplement and the use of human milk instead of riboflavin
supplemented infant formula as the primary diet. These
resul ts suggE.:st that the adequacy of riboflavin in the tissues
of the premature newborn is borderline and may become
inSUfficient if supplementation to the diet is not provided.
Is there a need, then, for riboflavin supplementation for
LBW infants, especially those being fed human milk? Ronnholm
(1986) analyzed the riboflavin status of 39 LBW infants.
Nineteen received supplemented human milk in which 0.3 llIg
riboflavin was added daily to mother's or banked milk samples
and 20 infants received no supplementation for a period of up
to 12 weeks after delivery. At 6 weeks post delivery, 47% of
those without supplementation had AC values indicative of a
deficiency. The riboflavin status of infants being
37
supplemented was significantly better. Consequently, Ronnholm
recommended that supplementation of infants most likely to
develop riboflavin deficiency was useful but warned that
dosage, time, and mode of administration to infants undergoing
phototherapy must be carefully adjusted to avoid unwanted side
effects. Further to this warning, it is interesting to note
that riboflavin can act as a photosensitizing agent which can
accelerate bilirubin photooxidation (Meizel at aI, 19'/8),
Sisson (1987) stated that intramolecular photoreduction of
riboflavin occurs in the presence of light by donation of
electrons from such compounds as amino acids, amines, and
NADH. In the process of aerobic photoreduction, flavins
catalyze the aerobic photooxidation of a number of substances
by reversible photoreduction and photosensitization, in Which
latter action triplet flavin transfers energy to oxygen to
yield singlet oxygen.
Because of these photochemical actions and the fact that
flavins are present in nearly all biological fluids and
tissues, riboflavin has a significant influence in neonotal
phototherapy (Sisson, 1987).
However, studies by Ennever et al (1983a, 1983b) showed
that standard phototherapy illumination in the presence of
riboflavin produced single- and dOllble- strand breaks in both
purified and intracellular DNA by both oxygen dependent and
independent reactions. since light activated riboflavin has
the propensity for tissue damage, it has been suggested that
3.
caution be exercised in providing large supplements of this
vitamin to neonates receiving phototherapy. Ennever and
fellow workers (1983b) suggested that there is potential for
the production of genetic damage even with the use of
multivitamin solutions exposed to phototherapy. This is
important since many LBW infants are fed intravenously with
solutions containing multivitamin formulations at the same
time they receive phototherapy.
3." FOLATE METABOLISM
Folates (Figure 3.4) are found in a wide variety of !'llant
and animal tissues mainly in the reduced methyl or formyl
glutamate forms. Folic acid is reduced by a two:> step reaction
to its coenzyme forn; (tetrahydrofolic acid) Which serves as
an intermediate carrier of hydroxyrnethyl, formyl, and methyl
groups (Keagy, 1985; Rodriquez, 1980; Mock, 1986).
'l'etrahydrofo1ates serve as acceptors or donors of one carbon
uni ts which are invol vcd in the following metabolic systems;
1) formation of glycinamide ribonucleotide and
5-amino-4-imidazole carboxamine ribonUcleotide in early purine
synthesis; 2) methylation of deoxymandylic acid to
thymidylic acid in pyrimidine nucleotide biosynthesis; 3)
amino acid conversions [i. e. serine to glycine, histidine to
glutamic acid, and homocysteine to methionine]; and 4)
generation of formate and its utilization (Shinton, 1972).
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Figure 3.'"
structure of folic acid and a 5-methyltetrahydrofolate
pentaglutamate
OH CH. ~oN~I)'~CH"""-U-I-''''~''"'~''''HI"'1'''"HIN~~ H
5-METHYL~TETRAHYOOOFOLATE PENTAGLUTAMATE
(S·melhyl-H4PteGlusl
Dietary folates are predominantly pteroylpolyglutamate
(PteGlu) derivatives. The process of folate absorption
requires their hydrolysis to monoglutamate derivatives prior
to folate transport across the intestinal mucosa (Halsted,
1979). Pte-Glu is absorbed predominantly in the duodenum and
jejunum by an active process stimulated by glucose and
eXhibiting saturation kinetics. At higher folate
concentrations, absorption follows first order kinet ics,
suggesting the presence of a second passive component for
transport (Brady et al, 1984). Metabolism of Pte-Glu to
5-methyl tetrahydroPteGlu during passage across the mucosa has
been observed and has led to the postulation that mucosal
metabolism plays a role in folate absorption. However, when
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large doses of Pte-Glu are administered only a small
proportion is methylated and much of the Pte-Glu can be
recovered unchanged in the ur:1ne. Thus methylation does not
appear to be a prerequisi te for absorption (Brady et aI,
1984) .
Polyglutamates, the main intracellular form of folate, do
not cross mammal ian cell membranes. It has been suggested
that polyglutamates enter the villous epithelial cells where
the peptide chain is removed by a-carboxylpeptidases and then
further reduced to tetrahydrofolates by folate reductases. In
this form folates enter the portal circulation (Shinton,
1972). These monoglutamate derivatives tire taken up by cells
by specific transport systems and metabolized
intracellularly to polyglutarnate forms which are retained by
the cells.
The liver may be responsible for the production or
maintenance of the major form of plasma folate,
5-methyl· tetrahydrofolate. When humans are given oral
Pte-Glu, the portal plasma initially contains mainly the
nonmethylated felates, whereas peripheral plasma contains the
r.1ethyl form at all times. Over time portal plasma folate
assumes the methyl form as well. Thus, folate absorbed
through the intestine enters the liver where it is converted
to the methyl form and then most is released back into the
circulation (Dencher et aI, 1976).
Plasma levels vary from 3-21 ng/mL in healthy individuals
(Shinton, 1972). These values are sex and age independent but
are affected by diurnal variation associated with meals. When
dietary intake is reduced, plasma folate levels fall ....ithin
a few days due to the cesoation of the exchange mechanism
observed with liver folate. Hoffbrand et al (1966) observed
that patients with serum folate levels less than 3.0 ng/mL
almost always had megaloblastic anemia or obvious red cell
morphological changes of folate deficiency.
Total content of body folate in adults is 70 mg with one
third (5-15 Ug/g) contained in the liver. Liver folate falls
to 1.5 jJ.g/g in about 130 days on a folate deficient diet with
megaloblastic changes. Folate is incorporated in red blood
cells during erythropoiesis and there is only a slight fall
during their life span. Red blood cell folate is a useful
indicator of body folate status with an average level of 300
ng/mL (range 160-640 ng/mL) (Shinton, 1972).
Folate is lost from the body in urine, feces, sweat and
saliva. The daily urinary excretion of intact folates for
adults is between 1-12 119 (Brady et aI, 1984); this is
approximately 1% of the daily dietary intake (Cooperman et aI,
1970). The amounts excreted are increased after injected or
oral test doses of folate. Measurements of urinary levels at
folate, with or without folic acid test doses, have not been
of value for evaluating folate nutritional status (Cooperman
et aI, 1970). An increase of formininoqlutamic acid (FlGW)
excreted in the urine after a histidine load, suggests a
folate deficiency. However, this test is not specific for
folate since the same is observed with a vitamin B ll deficiency
(Herbert, 1983). Tracer studies in humans indicate an initial
excretion of unllletabolized Pte-Glu together lIith 5-methyl-
tetrahydroPte-Glu and 10-formyl-tetrahydroPte-Glu following
oral or intravenous doses of labelled Pte-Glu (Brady et aI,
1984). With time, the urine contains labelled breakdown
products, presumably the acetamidobenzoylglutamate derivative
and labelled pteridines. However, over one half of the
radioactivity is excreted in the feces.
Denko et al (1946) reported that feces contain 5-15 times
the amount of folate ingested. possible sources of fecal
folate include unab. "bed dietary folate, folate resynthesized
by oral and intestir.aJ microflora, endogenous metabolism such
as that which is excreted in bile and saliva or from
degradation of gastrointestinal cells. Bile contains high
levels of folate due to enterohepatic cirCUlation of folate.
Polate concentration in bile ranges from 10-89 ng/mL, which
is two to ten times as much folate found in serum (Rodriquez,
1980) . In humans, total body folate stores turnover at an
estimated rate of less than n per day (Krumdieck et aI,
1978). Most of the folate in bile is reabsorbed in the
intestine. An estimated 0.1 mg folate is lost per day due to
incomplete absorption of biliary folates in normal SUbjects
(Brady et aI, 1984). In cases of folate malabsorption,
biliary folate loss may contribute significantly to ensuing
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folate deficiency.
Folate deficiency may occur via one or more of the six
possible etiologic mechanisms common to all nutritional
deficiencies (1. e. inadequate ingestion, absorption,
utilization and/or increased requirement, excretion, or
destruction) (Herbert, 1983).
Megaloblastosis, resulting from a deficiency of both
folate and vitamin Bl~' is due to a disturbance in DNA
syntheds. Deoxyuridylate is inadequately converted to
thymidylate because the amount of the coenzyme, 5,10-methylenc
tetrahydrofolate is reduced. In folate deprivation this
reduction occurs because of the reduction of folate in the
body whereas in vitamin Bl2 deficiency there is a decreased
amount of coenzyme (Herbert, 1983). Hypersegmentation of
polymorph nuclei occurs after seven weeks of folate
deprivation and during the eighteenth week macrocytic anemia
is observed. Florid megaloblastic anemia with gross changes
in bone marrow is associated with a shortened life span of
cells produced and leads to hemolytic anemia with jaundice,
leucopenia, and thrombocytopenia. Gastrointestina 1
disturbances include glossitis, stomatitis, and intestinal
malabsorption. Other organs affected include the cervical and
vaginal squamous epithelium, the ovaries and the testes,
reSUlting in infertility (Shinton, 1972; Herbert, 1963).
Skin disorders (Le. psoriasis, dermatitis, herpetiformis,
rosacea, eczema, eXfoliative dermatitis), obstetric disorders
(i.e. toxemia, accidental hemorrhage, abortion, and congenital
anomalies), neuropathy, and psychiatric disorders are symptoms
associated with folate deficiency (Marks, 1985).
The most common cause of megaloblastic anemia in infants
and children is folate deficiency_ Body folatE'. stores at
birth arc small and are rapidly depleted by requirements for
growth. Serum and red blood cell folate fall below adult
levels by the second week of life and remain below the adult
values for the first year of life (Herbert, 1983).
Little is known about the subclinical effects of excessive
folic acid intake. Some researchers found that meqadoses
produced r.lental changes, sleep disturbances, gastrointestinal
symptoms, malaise, and irritability. Others have not been
able to confirm these observations (Rodriquez, 1980; Aldaheff
at aI, 1984).
If a vitamin Bl2 deficiency exists, meqadoses of folate
will mask the anemia but do not prevent the irreversible
damage to the nervous system which occurs fAldaheff et aI,
1984). Ford et al (1975) suggested that excess folic acid may
have an adverse affect on the microbial popuJ.ation in the
intestine of infants by increasing the growth of
folate-requiring bacteria. High levels of folate may also
interfere with the action of drugs. For instance, folate and
the anticonvulsant, phenytoin, inhibit the uptake of each
other at the gut cell wall and possibly at the blood brain
barrier. Megadoses of folate may precipitate convulsions in
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persons whose epilepsy is controlled 1y phenytoin (Herbert,
1987). It has also been observed that very large doses ot
folate given parenterally to experi.ental animals lIIay
precipitate in the kidneys producing kidney dalllage and
hypertrophy (Herbert, 1987a).
The minimal daily requirement for adults is about SO pg
based on findings that daily parenteral administration at this
amount corrects folate deficient anemia (Herbert, 1987a). It
has been observed that about 90' of the North American
population consume adequate folate tor daily metabolic needs
but also enough folate to sustain a substantial folate storago
(more than 140 ng tolatejmL red cells) against periods ot
dietary deprivation (Herbert, 1987a). From these observat.1ons
the recommended daily intakes (ROI) for adults has been set
at 3 ~gjkg/d (Health and Welfare Canada, 1983). Factors which
affect folate requirements include growth, other dietary
factors, certain drugs, and infection. Increases in the
number of body cells or the rate of cell turnover affects
folate requirements since folates are required for DNA and RNA
synthesis. Therefore periods of growth, pregnancy, lactation
and innumerable pathological conditions increase the
requirement for folate (Rodriquez, 1980).
The availability of dietary folate may also affect the
requirements. For instance, the chemical structure of folata,
the cellulose content of the diet, naturally occurring
antagonists, glucose and the pH may affect folate absorption
(Benn et aI, 1971; corcino, 1975; Gerson et aI, 1971).
There is some evidence that compounds such as iron, oral
contraceptives, ascorbic acid, cobalamin, methionine, alcohol,
and certain drugs plus vitamin Bll deficiency interfere ..ith
the utilization and storage of folate (Rodriquez, 1980).
Many drugs affect folate metabolism and in sOllie cases
induce megaloblastic anemia. Por instance, methotrexate,
aminopterin, antimalarial drugs (pyrimethamine) and
antibacterial drugs (trimethoprim) inhibitors of
dihydrofolate reductase (Rodriquez, 1980). Anticonvulsant
drugs (diphcmylhydanto!n, primidane) and barbituates
antagonize folate status (Rodriguez, 1980). Prolonged
treatment with the bile sequestering agent, polidexide, will
produce folate deficiency in children (Ritland et aI, 1975).
The effect of infection on folate nutriture is n."lt well
established. Folate deticiency in people ....ith infections has
been attributed to low reserves, inadequate intake, loss
through emesis and diarrhea, increased granulocyte and red
cell turnover and i.paired absorption or utilization (Luhby,
1959; Mac lver and Back, 1960: Zuelzer and Ogden, 1946).
Many clinicians (Kende et aI, 1963; Khalil et aI, 1973; Mac
Iver and Back, 1960; Zuelzer and Rutzky, 1953) have reported
megaloblastic anemia due to folate deficiency in infants and
children with diarrhea, gastroenteritis, and respiratory
infections, especially in LBW infants and int'ants less than
six months. The diarrhea ceased when folate was administered.
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Others have reported that diarrhoa and infections preceded the
development o~ megaloblastic anemia suggesting that increase
folate requirements due to infection precipitated the ancmia.
Luhby (1959) concluded that in infants 2-5 Illonths old severc
infection was the principle cause ot megaloblastic anemia
whereas in infants 8-12 months. inadequate diet was the
principle factor.
Infants require about ten times as much folate as adul ts
on the basis of body weight. The recommended intake of 30-65
~g/d (Dallman, 1988) is provided by breast milk which supplies
approximately 50 /Jg/L (Herbert, 1987a; Dallman, 1988). The
RNI for Canadians recommends an oral intake of 50 ~g/d for
infants (Health and welfare Canada, 1983). Even though there
is little storage of folate at birth (Herbert, 1988). infants
fed human milk. or proprietary cow milk formulas are at little
risk for developing a folic acid deficiency (Ek and Magnus,
1980; Ek and Magnus, 1982; Salmenpera et aI, 1986; Tamura
et aI, 1980).
salmenpera and coworkers (1986) conducted an investigation
to assess whether prolonged exclusive breastfeeding provided
adequate folate nutrition for full term infants. Two hundrcd
Finnish mothers and their offspring participated in this
study. Infants who were weaned from breast milk receivcd
formula containing 35 ~g folate/L and folate status
determined b:y analyzing the plasma folate concentration. The
authors found that the exclusively breast fed infants had
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adequate plasma folate concentrations whereas after being
weaned plasma folate levels dropped rapidly 1n the formula fed
group and rose only after solid food was introduced.
Salmenpera et I'll (1986) concluded that the breast fed babies
were protected against folate deficiency whereas formula fed
infants may have marginal intakes even if the forrnula contains
the recommended level of folate. However, there are three
serious problems concerrdng this investigation. First, only
plasma folate concentrations were determined as a measure of
folate status. Secondly, the authors did not estimate folate
intakes from the milk feedings or solid foods which would have
a definite influence on folate nutriture. Lastly, the milk
folate content was not determined due to "technical
difficulties". The latter point could be of critical concern
since recommendations have been based on the amount of the
vitamin in breast mill:. Recent studies have shown folate
concentrations in milk in the range of 80-140 Ilg/L (Smith et
1'11, 1983; Tamura et 1'11, 1980) whereas earlier work estimated
folate levels between 2-50 .ug/L (Matoth et 1'11, 1965;
Ramasatri, 1965; Burland et I'll 19). Thus a formula
containing 35 J.Ig folate/L may not provide adequate folate for
this population.
Ek and Magnus (1979) studied 35 healthy breast fed infants
for their first year of life and assessed growth and folate
status as determined by plasma and red blood cell folate
concentrations. At birth and throughout the period of
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investigation they found that folate levels in both plasma and
red cells were significantly higher than that of the adult
reference group. Froll their results, Ek and Magnus concludod
that the folate status of breast fed infants was optimal and
suggested "that the optimal supply of the vita.in in
artificial nutrition should be the allo;,:~t of folate necessary
to maintain plasma and red cell folate conc~ntrations similar
to those found in breast fed infants".
As well, Ek and Magnus (1980, 1982) investigated the
plasma and red blood cell folate concentrations of infants fed
homemade cow's milk mixtures and infants receiving two
proprietary formulas (one containing 39 Jlg folate/L, the other
78 Jlg/L). They compared the folate status of these infants
to that of breast fed infants previously studied (Ek and
Magnus, 1979). They found folate deficiency in ten infants
fed the cow's milk mixtures and attributed this deficiency to
the loss of folate during the preparation of the formula. The
infants receiving the fomula with 39 j.lg folate/L had plasllla
and red cell folate levels significantly lower than the breast
fed babies whereas those receiving the second formula (78
j.lg/L) had folate levels similar to those recorded in the
breast fed group. Thus the authors concluded that the formula
containing 78 /Jg folate/L provided adequate folate for full
term infants. Ek and Magnus chose more appropriate parameters
to establish folate status than Salmenpera's group but they
also did not estimate folate intakes for their SUbjects.
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Smith et al (1985) conducted a study to assess possible
factors which may influence folate nutrition (If infants (Le.
the type of milk, total folate intake, and iron). They
determined the folate status (using serum and red cell folate
concen-=rations plus total intake) of 67 full term infants from
birth to one year of age. From their data, they found that
during the first 3 months infants exclusively fed proprietary
formula (160 119 folate/L) with or without added iron had blood
folate levels 1. 5 to 4 times higher than those infants fed
human milk (85 1l9/L) and adult controls. After the
intrOduction of solid food, blood folate levels pa.ralleled a
decrease in milk folate intake and the folate concentrations
were about the same in all groups. smith and coworkers
concluded that milk, regardless of the type, is an important
source of folate during the first year of life and provides
more than sufficient folate to maintain the blood folate
content well above acceptable limits. However, folate
deficiency has been reported in LBW infants who were fed
formulas based on heated or boiled evaporated milk (Strelling
et aI, 1979) or pasteurized milk (Matoth et aI, 1979).
The folate requirement for LBW infants should take into
account birthweight, rate of growth, and maternal folate
status. Determining folate requirements of LBW infants is
crucial since there is a dramatic drop of blood folate levels
after birth and an increased incidence of megaloblastic anemia
(Herbert, 19S7a). Megaloblastic anemia is lnostly seen 3-8
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weeks after birth and in those weighing less than 1700 9 at
birth (Rodriquez, 1980). Since folate is also required for
DNA synthesis which is essential for cellular proliferation,
rapidly growing LBW infants may need .o};e folate per unit body
weight than full term infants.
There has been much controversy over the need of folate
supplementation for LBW infants. stevens et al (1979)
conduct:ca a folate supplementation study on 246 LBW infants.
One group received 100 1J9 folate daily plus 10 mg elemental
iron from the third week after delivery until 12 months of
age. The second group received only the iron supplement for
the same period of time. They observed that the median red
blood folate levels remained within normal adult range in both
groups of infants and that weight gain was not affected by
folate supplementation. Thus Stevens and coworkers concluded
that they did not have SUfficient grounds to recommend folate
supplementation for the first year of life.
Asfour et al (1977) studied fully intakes of 20 Lebap\ese
infants. Folate intakes greater than 3.6 $1g/kg/d did not
raise hemoglobin levels or improve weight gain. However, it
was not stated if any of the infants wore of low birthweight.
On the other hand, Strelling et al (1966) found that in a
group of LBW infants not given folate ~\1pplemantation, 25\ had
megaloblastic anemia. It has been shown that a test dose of
folate disappeared trom the blood of LBW infants more rapidly
than in older SUbjects ..,ithout an increase in the urinary
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output of the vitamin (Shojania and Hornaday, 1970). Some
authors have interpreted this as an increase in utilization
and suggested supplementation of 50-200 1-19 folatejd for this
age group (strelling et aI, 1979).
Gandy and Jacobson (1977) studied the effect of folate
supplementation on the growth of 17 erythroblastotic infants.
They received either 2.5 or 5 mg of folate daily from about
the sixteenth day of life until they were J months of age.
Weight gain was followed for one year and compared to the
weight gain of 34 erythroblastotic infants not receiving
supplementation. By the end of the fourth month the treated
group's median centiles for weight had risen from the 40th to
the BOth. The untreated group's centile for weight rose as
well but only to the 50th centile. During the second half of
the year both groups' weight centiles decreased; to the 50th
centile for the treated group and to the 25th for the
untreated group. The investigators suggested that further
work was needed to determine if a shortage of folate during
the first year of life could lead to a decreased rate of
weight gain and also to impaired higher functions in the
central nervous system at a later age.
Could excess folate be potentially harmful to the growth
and development of the LBW infant? Folate has been shown to
have potent convulsive effects in experimental animals when
injected directly into the cerebral spinal fluid or the brain
(Hommes and Obbens, 1972). However, while studying folate
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transport in the central nervous system, Spector and Lorenzo
(1975) suggested that there may be an efficient homeostatic
mechanism in the blood-brain barrier which probably helps
maintain brain levels of folate within relatively narrow
limits.
3.5 V:tTAHIN BIZ (COBALAMIN)
Vitamin Bl~ (Figure 3.5) is defined as a group of
cobalt-containing corrinoids that have biological activity in
humans.
cobalamins 1
Humans and other animals contain three main
hydroxycobalamin, adenosylcobalamin, and
methylcobalamin (Herbert, 1987b). Methylcobalamin is
important because of its interaction with folate metabolism
and deoxyadenosylcobalamin because of its involvement in both
carbohydrate and lipid metabolism. cyanocot>alamin is the most
widely used form of cobalamin in clinical practise due to its
relative availability and stability. The conversion of
cyanocobalamin to the coenzyme form is catalyzed by an enzymG
system, vitamin Bl2 coenzyme synthetase, present in a large
number of microbes and human tissue.
Mammalian cells require cobalamin as a cofactor for two
enzymes; (1) homocysteine methyl transferase which catalyzes
the conversion of homocysteine to methionine, and (2)
methylmalonyl coenzyme A mutase which catalyzes the
rearrangement of methylmalonyl coenzyme A to succinyl coenzyme
A. Vitamin BI1 is also involved in nucleic acid metabolism
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throuryh its role in the regeneration of folate from the
5-methyltetrahydrofolate pool and may influence the syntheziz
of polyglutamyl forms of folate (Ellenbogen, 1984: Herbert,
1987b; Shinton, 1972).
Figure 3.5
structure of cyanocobalamin
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Absorption of vitamin BIZ takes place in the ileum either
by an active 0:- passive mechanism. Active transport is
mediated by the intrinsic factor (IF), a mucopolysaccharide
sccrQted by the parietal cells of the gastric mucosa. The
cobCllamin-IF complex attaches itself to specific receptors on
the absorptive surface of the ileum (Ellenbogen, 1984). It
!l;)S been recently hypothesized that the IF has two receptor
site::-.; one for B:~ and one for the ileal intestinal microvilli
(Herbert, 1987b). If is not identified in plasma so it is
presumed that an intestinal releasing factor splits it off and
13;: passes into the mucosal cell (Shinton, 1972; Herbert,
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1987b} .
Absorption may also occur by a passive lIechanisli which ~s
nonIF .editlted, and not dependent on the presence ot calciulll
ions or pH. This process accounts for the absorption of 1-)\
of the vitallin but becomes biologically significant when
pharmaceutical amounts are consumed. This mechanism is site
nonspecific and therefore, some absorption does occur through
the nasal mucosa, rectal mucosa, and the skin (Shinton,1972).
It should be noted that as the intake of vitalllin IJI~
increases, there is a reduction in tho percent of vitamin
absorbed. At intakes of O. 5 ~g or less, about 70% of the
vitamin is absorbed. A.t intakes of 5 JJg, the mean absorption
is 28\ (Herbert, 1987b).
The passage of cobalamin into the plasma begins
approximately 2-3 hours after eating and peak plasma levels
are attained after 8-12 hours. Host cobalalllins are found in
plasma attached to specific proteins, lIainly transcorrin
(transcobalalllin) I, II, III (Ellenbogen, 1984; Shinton, 1972.
Herbert, 1987b). The functional role of transcorrin J and III
are unclear. While crossing the intestinal mucosa cobalamin
is transferred to transcorrin II which facilitates the uptilke
of the vitamin by a large number ot' tissues. The binding or
the transcorrin II-cobalamin complex to the cell surface is
probably mediated by specific receptors which have not beon
identified. This binding is dependent on calcium ion::.,
inhibited by EDTA. and not temperature dependent (Ellenbogen,
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~984). The transcorrin II-cobalamin complex is degraded in
the lysosome, treeing the cobalamin. Some of the cobalamin
is used to synthesize methylcobalamin in the cytosol.
Many investigators have reported a total body cobalamin
pool of 2-2.5 mg in adults and the normal turnover rate in
humans is about 2.5 /1g/d (Heyssel et aI, 1966; Shinton,
1972). In healthy individuals cobalamins are found
principally in the liver. The vitamin Bt2 concentration in
the liver tends to increase with age (Hsu et aI, 1966;
Met.a.ren, 1981). A three week old LBW' infant was found to have
a liver cobalamin content of 28 /-Ig whereas an adult's liver
content averages 1. 5 mg (Ellenbogen, 1984). There are between
20-JO /-Ig of the vitamin found in the kidneys, heart, spleen,
~nd brain (Ellenbogen, 1984). The concentration of vitamin
BI~ in plasma or serum is between 200-900 pgjmL with values
less than 100 pgjrnL indicative of a cobalamin deficiency.
The main excretory pathways for vitamin Bl2 are through
the urine, bile, and feces. The total loss from the body per
day is about 0.1% of the body pool regardless of the pool's
size (Heyssel et al, 1966). urinary output of free cobalamin
(the only form available for urinary excretion) varies from
0-0.25 J..l9/d (Shinton, 1972; Ellenbogen, 1984). In pernicious
anemia and other conditions associated with cobalamin
deficiency, urinary excretion is reduced. Following TPN or
intravenous administration, 50-90% of the dose is excreted in
the urine within 48 hours (Ellenbogen, 1984). Patients with
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renal disease excrete cyanocobalamin more slowly than heal thy
individuals (Ellenbogen, 1984).
About o. 5-5 ~g of cobalamin per day is secreted into the
alimentary tract, mainly in the bile. The ileum reaosorbs
65-75% of the vitamin through the IF mechanism. Small amounts
of vitamin 8 12 enter the intestine from gastric, pancreatic,
and intestinal secretions. Unabsorbed cobalamin passes into
feces and with that derived from bacterial synthesis in the
colon could account for 3-6 1J9 daily depending on body stores
(Ellenbogen, 1984; Herbert, 1987b).
Cobalamin ston.'s in humans exceed the daily requirement
1000 fold and the small intestine contains lllicroflora which
can synthesize significant amounts of cobalamin (Ellenbogen,
1984). Therefore a clinical cobalamin deficiency due to
dietary inSUfficiency is not often seen. It can take
individuals consuming a vegan diet (void of animal products
which is the main dietary source of vitamin B12 ) 20-30 years
to develop a deficiency (Herbert, 1987b). However, some
reports (Jadhav et aI, 1962; Higginbottom et aI, 1978) have
demonstrated a BI2 deficiency in infants breast fed by
vegetarian mothers. The occurrence of severe cobalilmin
deficiency in infants whose nursing mothers' tissues are
depleted of cobalamin indicates the importance of the vitamin
to the growing child (Jadhav et aI, 1962: Herbert, 1987b;
Ellenbogen, 1984).
Inadequate absorption accounts for more than 95\ of
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vitamin Bl2 deficiency cases. The lack of IF secretion results
in the failure to absorb cobalamins and can result from
pernicious anemia, qastrectomy, or the destruction of the
gastric mucosa. It may take 5-7 years before any outward
signs appear since body stores are usually sufficient for this
length of time. Adult pernicious anemia is the most commonly
acquired cause for failure to assimilate cobalamins.
Pernicious anemia is an inherited autosomal dominant trait
chiefly affecting persons past middle age. The incidence in
the population is 1-2/1000. There is also a rare hereditary
form of congenital pernicious anemia that Clinically appears
early in life. The symptoms of vitamin Bl2 deficiency include
megaloblastic anemia, weakness, tiredness, pale and smooth
tongue, dyspnea, splenomegaly, leukopenia, thrombocytopenia,
achlorhydria, paresthesia, neurological changes, 108S of
appetite, loss of weight, and low serum cobalamin levels.
A cobalamin deficiency may manifest in less than three
years if a small intestinal defect develops from conditions
such as celiac sprue, tropical sprue, resection of the ileum,
or ileitis. In these cases there is no deficiency of IF but
a defect in the ability of the distal ileum to absorb the
cobalamin-IF complex despite its normal adsorption to the
surface microvilli.
There are three known inborn errors of cobalamin
metabolism. One resul ts in a transcobalamin II deficiency
causing megaloblastic anemia and other clinical symptoms early
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in life (Cooper ant', Rosenblatt, 1987; Ellenbogen, 1984).
Children respond well to weekly intramllscular injections of
1000 IJg of cyanocobalamin. The other two are errors of tissue
utilization characterized by a failure to synthesize one or
both of the coenzYllles leading to abnorllal entry of cobalalllins
into cellI;. M8gadoses of cyanocobalamin only partially
correct this defect.
Vitamin Bu appears to cause no toxicity in humans or
animals at levels several thousand times their nutritional
requirement (Herbert, 1987; Ek, 1987: Ellenbogen, 1984).
Daily cobalamin requirements have been estimated from three
types of studies; 1) the amount necessary to treat
megaloblastic anemia from cobalamin deficiency, 2) comparison
of blood and liver concentrations in norlllal and cobalamin
deficient subjects, and) body stores and turnover rates of
the vitamin. A dietary intake ot 1 /oig daily appears to
sustain most healthy individuals (Herbert, 1987b). In fact,
vegetarians require 1-1.5 IJg orally to raise cobalamin levels
and parenteral doses of about I IJg/d maintain patient:> with
pernicious anemia in complete hematological and neurologic
remission (Ellenboqen, 1984). To allow for variations in
absorption and other factors, the RNI for adults was set at
2 ~g (Health and Welfare Canada, 198)). The RNI for infants
was derived from the content of vitamin BII in bt"eastmilk and
the amount ot: supplementation needed to show a therapeutic
response to vitamin Bu in deficient infants of B12 deficient
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veqetarian mothers (Herbert, 1987b; Jadhav et aI, 1962). An
oral intake of 0.3 Ilg/d is reco_ended tor infants according
to the RHI for Canadians (Health and Welfare, 1983).
Vitamin BIZ deficiency is not seen in breast fed infants
(apart from inborn errors of metabolis.) unless their mothers
art! deficient. Jadhav et al (1962) examined 6 breast fed
infants from South India with megaloblastic anemia. The
abnormalities associated with this disorder were corrected by
administering small doses of vitamin Bn to these children
which suggested that this was a specific effect of vitamin B12
deficiency. In all cases, vitamin 8 12 deficiency was
attributable to either a dietary lack or malabsorption
syndrome in the mothers. Higginbottom and coworkers (1978)
studied a six month old infant who had been exclusively breast
fed by a strict vegetarian mother. The clinical presentation
of this infant (i.e. severe megaloblastic anemia, coma, and
hyperpigmentation of the extremities) suggested an inborn
error of metaboliSlI and he was found to have methylmalonic
aciduria and homocystinuria. Both the cl inical and
biochemical abnormalities resolved after therapy with vitamin
BIZ supplementation. This case emphasized the importance of
vitamin BIZ supplementation in breast fed infants of purely
vegan women.
The common neonatal disorder, necrotizing enterocolitis,
which can result in surgery with the resection of the terminal
ileus may affect nutritional intake and metabolism of vitamin
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BIZ_ Although much of the intestine has the ability to adapt
its function after surgery, this does not occur for the
absorption of vitamin Bl2 which is dependent on the presence
of specific receptor sites (COllins et aI, 1984).
Consequently, if there is inadequate vitamin B\2 absorption,
vitamin Bn deficiency will occur after hepatic stores have
been eXhausted. On the other hand, there are large liver-
stores of Bll at birth (27 /.19 for term infants and a smaller
reserve of 11 /19 for LBW infants) (Vaz Pinto et aI, 1975).
Thus the vitamin B12 content in newborns is rarely depleted
prior to one year of age. However, there is increasing
concern over vitamin B12 deficiency in LBW infants since the
developing brain is more susceptible to this deficiency than
the developed one. An infant who is vitamin B\2 deficient may
have neurological problems as well as megaloblastic anemia
(Johnson et aI, 1982}.
Consequently, Collins and coworkers (1984) decided to
assess the vitamin Bl2 absorption in 14 children aged 1-7 who
had ileal resections for necrotizing enterocolitis. All were
born prematurely and none were given vitamin B\~ supplements.
5i>: of these children had abnormal vitamin BI 7. absorption,
however, all had normal blood counts and serum vitamin I]l~
concentrations. Despite this finding, these authors suggested
that children with ileal resections should be on lifelong
vitamin Bn supplementation if they have abnormal vitan,in 131~
absorption.
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CHAPTER 4. 0 PROBLEM STATEMENT
The vitamin requirements for LBW' infants are uncertain.
'rhe aim of the present study was to determine the adequacy of
thiamin, riboflavin, folate, and vitamin Bu. of LBW infants
receiving 2 different levels of vitamins in their parenteral
nutrition with that of a group of LBW infants receiving
enteral feeds.
The present investigation was concerned with the adequacy
of the intravenous infusion of four of the water-soluble
vitamins; Le. thiamin, riboflavin, folate and vitamin Dll for
the l.BW infant. Thiamin and riboflavin play a role in
neurological function. A deficiency of either may result ::'n
altered brain metabolism. It has been shown that 20-\ of
infants born prematurely have minor or major neurological
handicaps by the first year of life (Fitzharding et al, 1976).
furthermore, phototherapy for hyperbilirubinemia has resulted
in riboflavin deficiency in this popUlation group (Hovi et aI,
1979). Folate is required for growth and erythropoiesis. At
birth, LBW infants have limited folate reserves and are in a
period of rapid growth. Thus they appear to have a increased
need for this vitamin. Vitamin 612 is a constituent of the
coenzyme, methylcobalamin , which is in~'r ,ived in folate
metabolism. Since there is a close interre.1.;tlonship between
folate and Bn metabolism and because serum B12 and folate can
be measured simUltaneously using a dual radioassay procedure,
6J
it was convenient as well as practical to study vitamin 8 12 ,
The objectives of this study were as follows:
1) to determine plasma levels of folate and vitamin 8 12 and
urinary thiamin, riboflavin, folate and vitamin Bl2
concentrations of LBW infants receiving 2 levels of
intravenous vitamin administration during parenteral
nutrition; one level will be that level currently
recommended (60\ of the amount recommended for full term
infants) and the other level will be 40' of the amount
recommended for full term infants which still falls within
the minimal advisable oral intakes for LBW infants (Table
4.1) .
2) to determine erythrocyte transketolase and erythrocyte
glutathione reductase activity, which are functional
assays of thiamin and riboflavin status, respectively.
3) to measure the same parameters in infants receiving a
commercially available formula designed for LBW infants.
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TABLE 4.1
C!OMP08I'I'I:ON-MVI-PEDIATRIC
Minimal Advisable Oral 3 mt 2 mL
Intake per day* per day per day
'l'hlill!1in (mg)
J~ilJoflavin (mg)
vi t.dmin BI? (JLg)
I'nJ"te (JLg)
0.25-0.50
0.34-0.68
0.15-0.30
10-65
0.72
0.84
0.60
84.0
0.48
0.56
0.40
56.0
hi\d.-Ipted from American Academy of Pediatrics, 1967 i Fomon, 1974.
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CH~PTER 5.0 METHODS
5.1 I:NTRODOCTION
Methods of vitamin analysis fall into three categories;
animal, Ilicrobiological, and chemical assays. Animal assays
determine vitalllin availability to an animal using growth
measurements and repletion tests. The principle disadvantages
include length ot time (I.e. 6-8 weeks for a growth test),
cost, and variable results depending on the group of anillals
and techniques used, and interference from intestinal flora
that can synthesize certain vitamins and confound results
(Machlin, 1984; Augustyn et aI, 1975).
Microbiological procedures include fermentation and
growth of bacterid, yeasts, molds, or fungi. These methods
consume less time, are less expensive and yield 1II0ro
reproducible results than animal assays. However, antibiotics
and other substances (Le. metabolites) lIay interfere with the
interpretation ot results (Machlin, 1984; Augustyn et al,
1985). Manual and automated chemical assays are accurate,
rapid, and economical, and therefore, Illore applicable to
routine determinations.
5.2 SUBJECTS
The study group consisted of 48 LBW infnnts allocated into
three groups; parenterally fed infants (PAR2 ilnd PARJ) ilnd
enterally fed infants (ENT). All LBW infants born at st.
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Clare's Mercy Hospital or the Grace General Hospital after May
<\, 1987 were eligible for the study if they weighed ,5.1750
gr'ams at birth, were free of congenital anomalies, and if
parental consent was obtained. Consent was obtained once the
study had been fully explained by either the nurse in the
neonatal uni.t or by the investigator (appendix A and B).
SUbjects were removed trom the study if they presented with
low urine output (5 24 mL/kg/dj or they developed cholestatlc
jaundice (direct bilirubin more than :2.5 mg/lOO mL) .
The control group (ENT) consisted of 18 infants born at
the Grace General Hospital who were receiving enteral feeds.
The parenterally fed group of 30 infants were transferred to
the Janeway Child Health Centre's Neonatal Unit within two
days of birth. These infants received TPN and were randomly
assigned to a group (PAR2) receiving 2 mL or 40%: of the vial
of the multivitamin supplement, MVI-Pediatric (McGraw
Laboratories) or to a group (PAR3) receiving 3 mL or 60% of
the vial. lin infant was def.ined as "receiving TPN" if less
than 25% of its energy intake was obtained from enteral feeds.
Information regarding diagnosis, gestational age, birthweight,
and weight throughout the study was collected from hospital
racords.
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5.3 SAMPLE COLLEC'l'ION
5.3. 1 BLOOD COLLECTION
Blood samples were collected prior to the initiation of
enteral or parenteral feeds, when possible. SUbsequent blood
samples were collC1cted at 7, 14, 21, and 28 days. All sa.ples
were collected by heel prick.
One mlllilitre (I mL) of blood was collected in
heparinized microtainers (Becton Dickinson) with one drop of
sodiulll heparin added. One hundred microlitres (JlL) of whole
blood was transferred to microtubes. The remaining blood was
centrifuged at 1000 RPM for 10 minutes. The plasma was
separated and transferred into polyethylene microtubcs and
frozen at -7C·C. The red cells were washed with normal saline
four to five times before dilutions were prepared. Two 50 ilL
aliquots of red blood cells were diluted with 950 JiL of
distilled water tor the riboflavin assay and two 200 1J.L
aliquots of red blood cells were diluted with 200 lolL of
distilled water for the thiam.in assay. All samples werc then
frozen at _70· C until ani11ysis.
LBW infants may receive blood transfusions for four
reasons; 1) to replace acute blood loss, 2) to replace
chronic blood loss, 3) to treat hypotension, and 4) to
reverse the chronic anemia sometimes zeen at 7 to 8 weeks of
age (Joshi et aI, 1987). Therefore, ten samples of transfused
blood were analyzed for thiamin, riboflavin, and folat:c
6'
concentrations.
5.3. 2 URINE COLLECTION
Twenty-four hour urine collections were obtained prior
to the initiation of enteral or parenteral feeds, when
possible. Subsequent urine samples were collected at 7, 14,
21, and 28 days.
Initially urine collecting bags (Hollister U-Bags) for
felnale infants and 10 mL polyethylene tubes for the males were
used for urine collections. The success of these methods
depends on constant observation and prompt emptying which was
not feasible in this study. ce-nsequently, (especially with
respect to the girls) more urine was lost than acquired and
only rough estimations of total urinary <.ltput volumes could
be made.
l\. collection method that would not interfere with patient
care and would allow for 11 r.lore realistic 24 hour output
Volume was needed. A "metabolic" bed, suitable for an
isolette, was modified from one that was in the possession of
Dr. Wayne Andrews, Neonatologist at the Janeway Child Health
centre. The frame of the bed was made of plexiglass (Appendix
C) and is 53.4 " 30.5 x 7.7 em. Bed sheets were made from
Swedish Nitex Mesh (Appendix 0) allowing urine to seep through
to the collecting pan and exclUding the feces. The mesh sheet
sometimes caused skin irritation and therefore elbows and
knees of these infants were covered with gauze. Urine was
69
collected in bro.."n Nalgene bottles and stored at -7o"e until
analyzed.
5." VI'l'J\HIN ANALYSIS OF BLOOD SAMPLES
5.4.1 THIAMIN
Both blood and urinary excretion of thiamin are only a
reflection of the immediate intake and may not be a reliable
index of tissue stores, distribution, or actual biochemical
functioning (Sauberlich et aI, 1974). Thus these values may
be of limited value for the interpretation of actual thiamin
status. In controlled human studies (Sauberlich et aI, 1974)
a relationship has been found to exist between thiamin intake,
urinary excretion, and erythrocyte transkatolasa activity.
In the present study the transketolase stimulatory af feet
or the thiamin pyrophosphate (TPP) effect, a functional assay
developed by Brin et al (1965), was used to determine thiamin
status. Transketolase, a TPP dependent enzyme, catalyzes the
following two reactions in the pentose phosphate pathway:
TraT\sketolase-TPP
(1) Xylulose-S-phosphate + ribose-5-phosphate
sedoheptulose-7 -phosphate + Gl yceraldehyde-3 -phospha to
Transketolase-TPP
(2) Xylulose-5-phosphate + erythrose-4-phosphate~
fructose-6-phosphate ... Glyceraldehyde-3-phosphate
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'l'ri.lnskotolase is found within red blood cells and is
independent of changes in extracellular plasma (Brin et aI,
1965). As thiamin deficiency becomes more severe, thiamin
becomes limiting in the body cells and the available TPP
becomes depleted resul ting in a decrease of transketolase
activity. Thus the TPP effect measures the extent of
depletion of the transketolase enzyme.
Ilemolyzed red blood cell (RBC) samples were incubated in
a buffered medium wit.h an excess of substrate (ribose-5-
phosphate). The tUbes were pre incubated for 30 minutes eit.her
in t.he presence or absence of excess TPP (Brin et aI, 1965).
'rho supernatant was prepared by following the incubation chart
('l'able 5.1). Following an incubation period of 60 minutes at
J7"C, the tubes were centrifuged for 10 minutes and the
supernatant was saved for determining the amount of pentose
utilized. During the first incubation period, 100 j.IL of
substrate was added to produce an equilibrium mixture of
ribose-5-phosphate, ribulose-5-phosphate, and xylulose-5-
phosphate. The remaining pentose was measured in the
supernatant (Table 5.2). These compoun.... s are converted to
furfural and furfural derivatives by concentrated Hel and the
condensation of a polyhydric phenol (orcinol) in the presence
of metal ions (Fe++) to form colour complexes. These
compounds have absorption maxima at 670 nm and the absorbances
were read against a blank set at zero in a Perkin Elmer 200
spectrophotometer.
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T~BLE 5.1
ERYTIfROCYTE 'I'RANS)I;ETOUSE ACTIVITY (TPPE \)
INCU8ATION CHART
TUBES tlEtiOLYSATE BUFFER TPP INCUBATE SUBSTRATE INCUBATE 5\ TCA
(fIll~) (TIlL) (IlIL) (rnL) (mL)
...
-
V ,. 0.1 V 6 • , V
0 0 0
0.4 R '0 0.1. R 6. , R
T T T
0.1 0.' - E - E , E
X X X
... 0.1
TAIL! S.l
UYTHROCY'T! 1'1tANSUTOLA.S! ACTIVITY (UP! I)
PENrOSE UTIUZATION D!TUMlNATION
TUBES FILTRATE PENTOSF. OlSTlLLED ORCINOL BOILI"'C COll)
(IIIL) (IIIL) WATER (~L) WATER IC,
(IIIL) BATH BATH
0.' l.] 6.5 V All All
0 tube. tubes
0.' l.] 6.5 R for 20 for S
T Din. nln.
0.' l.] 1•. SE
X
0.1 1..4 '.s
:::
STDS o.s 1.0 '.S
STOIO 1.0 o.s '.S
BLAI'Il: 1.5 U
Orcinol vas added at 1 minute intervals to each tube
All tube. flre rlad asaln.t a blflnk 811; It ';Iro at 670 TVlI
The concentrations of these derivatives are a measure of
transkptolase activity. The TPP effect reflects the
proportion of transketolase which was not saturated with TPP.
The amount of pentose utilized per mL hemolysate per hour WClS
calculated using the calculations outlined in Appendix E.
An increase in enzyme '''':tivity rcsultinq from added 'l'pp
is referred to as the TPP effect. Values obtained without 'rl'l~
represent absolute enzyme activity and are dependent upon the
enzyme available in the erythrocytes. Addition of TPP permits
an estimation of the amount of apoenzyme uncomplexed as well
as of the maximum potential transketolase activity. 1\ 'I'PI'
effect of greater than 15\ is indicative of a thiamin
deficiency (Brin et aI, 1965). A severe deficiency is
demonstrated in humanl; with a TPP effect of 25\ or more
(SauberHch, 1965).
5.4.2 RIBOFLAVIN
The functional test (Tillotson and Baker, 1912).
erythrocyte glutathione reductase (EGR) activity, was used to
assess the nutritional adequacy of riboflavin. EGR cata1y:,:es
the reduction of oxidized glutathione (GSSG):
NADPH (NADH) + H' + GSSG ------)0 NADP' (NAO') + 2GBH
This assay is performed spectrophotometricelily requiring only
small quantities of blood and is based on the determination
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j
of the activity of EGR in the presence and absence of added
coenzyme, FAD. The degree of stimulation resulting from the
in vitro addition of FAD is expressed in terms of the activity
coefficient (AC) (Appendix F).
The assay mediulG was prepared in duplicate as outlined
in Table 5.3. The modium was incubated at 37GC for 811inutes
in the cuvette chamber of Perkin Ellller 200
spectrophotometer. Following incubation, 100 ilL of NADPH was
added to each cuvette. The absorbance of N1I.DPH at 340 nm WilS
measured for 5 minutes.
The bC is calculated using the following equation:
AC '" Reduction of absorbance of NApeH with FAp
Reduction of absorbance of NADPH without FAD
Normal SUbjects have an AC equal to 0.9 to 1. 2 indicatinq
little or no stimulation. In riboflavin deficiency a marked
stillulation is observed and this is associated with a
decreased urinary output of ribcflavin (Tillotson and Baker,
1972) .
The AC is age and sex independent whereas there are ago
and sex differences encountered with urinary excretion of
riboflavin. Animal studies provide evidence that deficiencies
of other vitamins such as thiamin, folate, pyridoxine, ond
vitamin C along with a decreased caloric intake do not
invalidate the interpretation of the FAD effect (Sauberllch
et aI, 1974). Uremia and cirrhosis of the liver may compound
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interpretations (Tillotson and Baker, 1972; Selhub and
Rosenberg, 1984).
5.".3 FOL),TE AND VITAMIN Bu:
A dual radioassay kit purchased from Becton Dickinson
(SifllulTRAC-S) was used to analyze both RBC folate and plasma
folate concentrations as well as plasma vitamin Bl~ lev~ls.
'l'he basis of this assay is competitive protein binding as
explained by the following equation:
Labelled "Folate or -6-812
Unlabelled folate or Bu j
;B12 or ·Folate-Binder
+ Binder
"
Bu or folate-Binder
Unlabelled vitanlin competes with labelled vitamin for the
limited number of binding sites and thus reduces the amount
of labelled vitamin bound. Consequently, the leval of
radioactivity bound is in-.."'::Lsely related to the concentration
of the vitamin in the serum or plasma.
The folate binder included in this kit is derived from
milk. The pteroylglutamic acid form of folate (PGA) is used
for the sta.ndards and tracer in an incubation mixture at pH
9.3. Both PC1\. and S-methyl tetrahydrofolic acid (MTFA) have
equal affinity for thC:! solid phase milk binder at pH 9.3 but
PGA is more stable in solution than MTFA.
For vitamin 812 the binder is purified intrinsic factor
(porcine) which is specific for cobalamin. The intrinsic
factor and the folate binder are covalently linked to a solid
support.
Polyethylene microtubes were numbered for standards and
samples according to Table 5.". This assay commences by
destroying endogenous serum binders through heat denaturation
(boiling for 15 minutes). After boiling, a constant amount
of binder is added. The tubes are then incut..lted at room
temperature for 60 minutes to allow the competitive binding
reaction to take place. The sepan'tion of bound and free
folate and vitamin BI~ is achieved by centrifugation. 'I'he
supernatant (free molecules) is then decanted and the bound
(pellets) are counted for one minute with a scintillation
(gamma) counter (Beckman Gamma 5500).
From the calculations described in appendix G, a standard
curve is plotted on logit-log paper (appendix H). The
concentration of vitamin Bl~ or folate in the samples can be
obtained from the standard curve and corrected by the dilution
factor.
The normal value for humans for plasma folate is 2-45
ng/mL and for RBC folate >110 ng/mL (Becton Dickinson, 1982).
Values lower than these are indicativp of a folate deficiency
(Herbert, 1987a). For plasma vitamin 8]2 the normal range is
between 200-900 pg/mL. Serum vitmnin BIZ levels w~ll above
1000 pg/mL are suggestive of either liver disease or
myeloproliferative disorders (Herbert, 1987b).
7B
TABLE 5.4
RADIOA88AY-FOLA'1'E AND VITAKIN Bu _ PROCEDURE
TUBE STD SAMPLE WOnKn~G INCUBATE BLANK BINDER InCUBATE CENTRIFUGE
J,4L J,4L TRACER REAGENT JJ.L
SOLUTION JJ.L
.L
1,2 1000
l,' 200A* - 1000 200
5,6 200A 1000 At 200 At At
"1,8 200B 1000 100·C 200 room 10009
9,10 200C 1000 for 200 temp (3.5
11,12 2000 1000 15 min. 200 for min_I)
D, ]4 200E 1000 Cool 200 60 for
15,16 200F 1000 to 200 min. 10 min
1"/,18
-
200 1000 18-25·C 200 in <in
ate. 200 1000 200 dark cold)
*11, Il, C, 0, E, F refer to standards of differing concentrations of
folate and vitamin Bla provided in the ki-t.
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VITAMIN ANALYSIS OF URINE SAMPLES
5.5.1 THIAMIN
To determine urinary thiamin, a modified thiochrome
procedure was used (Leveille, 1972). Thiamin can be oxidizod
to thiochrome by alkaline potassium ferricyanide. The
fluorescence of thiochrome can then be measured. The main
problem with this method has been the presence of unidenti f ied
fluorescing substances found in varying amounts. This problem
has been solved (Leveille, 1972) by either isolating thiamin
or by using a blank to correct for the fluorescence due to
these unidentified substances. The fluorescence measured is
proportional to tho concentration of thiochrome and thus to
the amount of thiamin in the sample.
This assay uses a 3 tube method to determine urinary
thiamin excretion as outlined in Table 5.5. The first tube
(A) contained the thiamin standard which corrected for any
quenching of fluorescence produced by the individual urine
sample. Tube B contained the urinC' sample to be measured and
tube C was the blank. Tne blank was prepared by adding sodium
hydroxide and benzene sulphonyl chloride to the £\ample in
order to block the oxidation of thiamin to thiochrome.
The isobutanol layer was transferred to fluorometer tubes
and fluorescence was then measured using a Perkin-Elmer LS-5
spectrofluorometer. The excitation wavelength WdS 365 nm and
the emission wavelength 435 nm. The excitation slit width was
so
TABLE 5.5
URINARY THIAHIN ASSAY (THIOCHROME PROCEDURE I
REAGENTS TUBE TUBE TUBE
COMMENTS
URINE (IIlL) Vortex all
tubes and
wait at
1'llJAMIN (mL) least 1 min
(O.2 1J9/mL)
WATER (mL)
1 N NaOH (mL)
*I3SC (drops)
**OXIDIZING 2. S 2.S 2.S Vortex and
IH::AGENT wait 50-60
·sec.
IIz0 z [;)(IU Vortex(drops)
ISOBUTANOL (mL) 10 10 10 Cap and
vortex
*l3anzene Sulphonyt Chloride
"oxiding Reagent: 2 parts 2' potassium terricyanide to 4 parts 40'
NaOIl
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5 nm and the emission slit width was 5 nm for baseline urines
and slit widths of 5 nm and 3 nm were used tor all otl\.::r
samples, respectively. For reagent preparation and
calculations refer to appendix I.
5.5.2 URINARY RIBOFLAVIN (FLUOROME'l'RIC' APOPROTEIN
TITRATION METHOD)
In solution individual proteins fluoresce as do flavins
which hav~ a separate and distinct fluorescent spectrum. When
flavins bind with equimoh..r quantities of their respective
apoprotein the fluorescence of both the flavins and protein
are almost completely quenched. This quenching of
fluorescence makes possible the direct titration of the
apoproteln with flavin which is the basis of this assay
(Tillotson and Bashor, 1980).
Riboflavin fluorescence is quenched when it binds egg
white flavoprotein. The concentration of urinary riboflavin
is calcUlated from the difference bet~~een the fluorescence
before and after the apoprotein titration.
Fluorescence was determined in a Perkin-Elmer LS-5
spectrofluorometer. The excitation wavelength was 45(1 n!;j and
the emission wavelongth was 520 nm. The excitation slit width
was 5 nm and the emission slit width was 20 nm for all
samples. The standard or sample was transferred to the
cuvette and an initial fluorescence was obtained. Then 10 ItL
of apoprotein was added and the fluorescence recorded. Ten
.2
(10) I!L aliquots of apoprotein were added until the same
fluor<!scence reading was obtained after three consecutive
additions of apoprotein. A standard curve of the change in
fluorescence units against the riboflavin concentration was
plotted. The concentration of urinary riboflavin was
calculated froa the standard curve. For reagent preparation
reter to appendix J.
5.5.3 FOLATE AND VITAMIN B12
There is no assay currently available for determining the
urinary excretion of folate and vitamin Bu. Therefore, the
radioassay, the method used to determine blood levels, was
carried out to assess its adequacy for determining urinary
excretion levels usir,g the Method of Standard Additions
(Beatty, 1978) (Figure 5.1).
Accurate determinations can be made without eliminating
interferences by making the concentration calibration in the
presence of the interference. The standards are added to
portions of the sample, thereby letting any interferent
present in the sample also affect the standard.
The urinary methylmalonic acid test is a well established
method used to diagnose cobalamin deficiency (Chalmers and
Lawson, 1982). Twelve urine samples (4 from each stUdy group)
were analyzed by the Janeway Child Health Centre's laboratory
for methylrnalonic acid. Methylmalonic acid was measured
quantitatively by gas chromatography mass spectrometry using
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figure 5.1
Method of Standard Additions*
Adapted from Concepts, Instrumentativn and Techniques in Atomic
Absorption Sepctrophotometry
R.D. Beatty, Perkin Elmer corporation, 1978
A sample is taken and split into 3 portions. Nothing is added
to the first portion; different amounts of standard are added to
portions 2 and J. Finally, all portions are diluted to the same
volume so that the final concentrations are the same. Only the
amount of added analyte differs by a known amount. If there is no
intorfcrence in the sample, then the final concentration vs
concentration of the added standard \oI'auld be parallel to the
<lqllQOUS standard calibration. If there is interference, the amount
of the analyte in the unspiked sample will be reduced by this
interference. HQ\~ever, the increase from added standard will also
l>c reduced by the same amount. Therefore, a straight line will
I"OSlllt but because of the interference, its slope will be different
from that of the aqueous stand~~=s. By continuing the
cOllcentr<ltlol1 cal ibration on the abscissa backward from zero and
oxtr.Jpolating the calibration line backward until it intercepts the
concentration axis, the concentration of the unspiked sample can
be determined.
.,
selective ion monitoring (Chalmers and Lawson, 1982).
5. 6 DIE'l'ARY :IN'l'AU DATA
Energy, thiamin, riboflavin, folate, and vitallin Bl :
intakes were calculated from product monographs. Due to the
mUltidisciplinary nature of neonatal intensive care for LDW
infants, not all the prepared. TPN solutions were infused over
a 24 hour period at certain times. Therefore, the infants in
the parenteral groups did not always receive their assigned
2 lIlL or 3 mL of the multivitamin supplement.
5.7 PARENTERAL NUTRITION :INFUSATES
Three 200 lllL samples of parenteral nutrition solutions
.....ere exposed to normal conditions in the Neonatal unit at the!
Janeway Child Hell1th Centre for a 30 hour period. For the
first 12 hours aliquots were removed every 2 hours starting
with time zero and thereafter, every 4 hours. An equal amount
of 0.1 N HCI was added to the vial containing the TPN lIixture
to be used for determining thiamin concentration for the
purpose of stabilization. The samples were protected from
light and frozen immediately upon removal from the TPN bags
at -20Ge. The samples were analyzed for the thiamin, folate
C'nd BIZ levels following the procedures outlined in section
5.5.1, and 5.5.2, respectively. As well, MVI-pediatric was
analyzed for these 3 vitamins using the same analytical
techniques.
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Riboflavin is present as FHN in MVI Pediatric and
therefore, in the TPN solutions. The tluorometric apoprotein
procedure used in this study for detllrmining urinary
riboflavin is specific for riboflavin and only binds loosely
with fMN. Since no technique was available to £.nalY2e FHN in
this laboratory, riboflavin was not moasured in the vial of
MVI-Pediatric or TPN adMixture.
5.8 STATISTICAL lI.NALYSIS
All data were entered onto the VAX computer system.
Because sUbjects were placed on enteral feeds once clinically
indicated, subjects dropped out of the PAR2 and PAR3 groups
rapidly. Theret'ore, changes in vitamin levels could not be
analyzed using the repeated t1easures analysis of variance.
To evaluate if there was an effect at time on each variable
within groups, a statistical formula (Appendix J<) was designed
specifically for this problem by Dr. Sutradhar, Department of
Mathellatics and Statistics, Memorial University of
Newfoundland. This procedure and oneway analysis of variance
was used to assess di fferences between groups at each sampling
time for each vitamin. Onaway analysis of variance was also
used to determine differences due to birth....eight and
gestational age. Studlmts t-test was used to determine if
there was a difference due to gender or acquiring blood
transfusions within each group. Oneway analysis of variance
and student T-tests were done by SPSSX computerized
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procedures. Linear regression \<las used to determine if there
was a correlation between dietary thiamin or riboflavin and
urinary output of these two vitamins as well as dietary folate
and vitamin B12 and their plasma concentrations.
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CRAPTER 6.0 RESULTS
6.1 INTRODUCTION
Demographic information regarding gestational age,
birthweight, and sex is presented in Table 6.1. There ...as no
significant difference in gestational age or birthwelght
between the three study groups. No effect due to gender
differences was observed within the groups for each
biochemical parameter examined.
TABLE 6.1
OEMOGR1I.PHIC INFORMATION fi ± SD)
ENT P•• P••
Z mL 3 mL
NUMBER OF SUBJECTS ,. 15 15
BTRTHWEIGHT (9) 128l±271 1137±231 1133±293
GES'rATIONAL AGE 29.6±l.7 :la.5±l.S 29.4±2.l
(WEEK)
SEX FEMALE 11 3
MALE 4 12
.8
The two major prematurity related medical problems
affecting these infanta were respiratory distress syndroJlle and
hyperbilirubinemia. Fifty per cent of the tNT infants, flO\
of the PAR2 group and lOOt of the PAR3 group were diagnosed
liS having respiratory distress syndrome. Hyperbilirubinemia
Iofas clinically presented in 61t of the ENT group, 13\ of the
PAR2 group, and 60\ of the PAR3 group. Seventy-nine per cent
of the infants received an antibiotic and 69t received
theophylline for apnea of prematurity as part of their medical
treatment during the study period. Forty-eight per cent of
the infants underwent phototherapy, the treatment for
hyperbilirubinemia, in their first week of life.
Only 50\ of the PAR2 and PAR3 infants were sti 11
receiving parenteral nutrition by the begInning of the second
week and by the beginning of the third W'eek less than a third
of the infants Who started the study received TPN. Some
infants in the parenteral groups failed to complete the study
because of concurrent illness involving additional treatment
or because of their progression to complote enteral fccd~.
During the course of this investigation one child in the PAR3
group died. Because there were few samples, if any, available
by week 3, parameters measured at this week were not included
on the graphs. Ho....ever, they are listed in the tables
provided. Not all the prepared feedings were infused over a
24 hour period. Table 6.1a shows the actual percentage of
pi!lrenteral fluid intake which was achieved for the PAR2 and
.0
PARJ groups. From these resul ts it appears that the PAR2
group anI j' received approximately 1.5 mLjd of MVI-Pediatric.
Twenty per cent of the infants received blood
transfusions at some point in the study. No differences in
erythrocyte glutathione reductase activity, erythrocyte
transkctolase activity. or RBe folate concentrations were
found between those who received transfusionS' and those who
did not. Thus, the values were pooled.
Body weight was used to assess growth. No significant
difference occurred between the 2 parenteral groups at any
sampling time throughout the study period, suggesting that the
different levels of vitamins infused did not influence growth.
However, the sUbjects in the ENT group were approximately 300
9 larger than the sUbjects in the parenteral groups by the
second week (Figure 6.1). The EUT infants were significantly
larger than the PAR] infants at the 0.05 level of
signi f icance.
There was significant difference in the amount of
energy received by either the PAR2 or PARJ groups (Figure
6.2). On the other hand, the ENT infants received twice as
much energy as the infants receiving TPN by the second week
(p < 0.05). The mean percentage of energy and vitamins
prov ided by enteral feeds for the parenteral groups was only
4% of the total. Consequently, the enteral intake was a minor
contributor of these nutrients.
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TABLE 6.1a
PERCENT I") TPN RECEIVED BY PAREN"l'ER1\L GROUPS
(Jt ± SOl Cn)
PAR2 PAR)
\ieek 1 76:t26 7l:t47
(13) (13)
Week 2 78:t18 91±lO
(6) (7)
Week) 82±12 64±22
(3) (')
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6.2 VITAMIN CONCENTRATIONS IN TPN ADMIXTURES AND MVI-
PEDIATRIC
Table 6.2 lists the vitamin concentration in three TPN
50lutions exposed to normal conditions in the neonatal unit
at the Janeway Child Health Centre over a 30 hour period.
There wa!; no degradation in the thiamin level in TPN solutions
over the 30 hour period. The actual amount measured was, on
average, 38% more than the level expected. The thiamin
concer.tration in MVI-Pediatric was found to be 35\ more than
the amount listed on the product monograph. Due to this
result, calculated intakes ....ere adjusted by 38% for the
parenteral groups (Figure 6.3, Table 6.3) and used for ths
interpretation of thiamin status in this investigation.
The folate concentration in the TPN admixtures declined
by 25\ 3fter 24 hours. However, the level of folate detected
(.028 1\1g folate/mL MVI-pediatric) in the parenteral solution
at time 0 and in the vial of MVI-Pediatric (Table 6.2) was the
concentrat.ion expected. Intakes were calculated using the
amount of folate appearing on the package insert of MVI-
Pediatric for the PAR2 and PAR3 groups.
Vitamin 8 12 in the parenteral solution was stable over
time (Table 6.2). The amount of vitamin 8 12 recovered in the
multivitamin formulation was 90% of the level expected.
Thirty-three percent less vitamin B12 was measured in the TPN
admixture at time 0 than the level expected. In this study,
intakes of vitamin 8 12 by the parenteral groups were adjusted
.4
'I'ABLE 6.2
VITAMIN CONCENTRATIONS IN TPN ADHIX'I'URE AND MVI-PEDIATRIC
THIN-lIN FOLATE VITAMIN Bl2
(mqjmL) (mgjmL) (J.lgjmL)
TPN-Tirne 0 h 0.330±0.123 0.O28±0.0 0.133±0.009
(admixture)
TPN-Time 24 h 0.370±0.O93 0.O21±0.001'" 0.133±O.OO8
(admixture)
TPN-Time 30 h O.310±O.030 0.021±0.00Z'" o .133±O. 004
(admixture)
HVI-PEDIATRIC O. 330±0. 001 0.028±0.0 o • 180±0 • 005
PRODUCT MONOGRAPH 0.240 0.028 0.200
*Significantly d;fferent than Time 0 at the 5% level.
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downward by 33%.
6.3 THIAMIN
Figure 6.3 and Table 6.3 show the dietary thiamin intakes
for each group. Two millilitres of MVI-Pediatric added to the
parenteral solution supplied 0.48 mg of thiamin daily whereas
J mL supplied 0.72 mg. The PARJ infants received
significantly more thiamin than the infants in the ENT group
in the first and second weeks. The PAR2 infants received more
of the vitamin than the ENT infants by week 2. None of the
infants had biochemical evidence of a thiamin deficiency as
measured by the thiamin pyropho!Jphate effect (TPPE) (Figure
6.4, Table 6.4). There was no significant difference between
groups at any time period ,lith respect to the TPPE but there
'Nas a time effect found between the baseline and week 1
results for all three groups. No difference was seen between
the J groups at weeks 1 through J regarding transketolase
activity (Table 6.4a). The TPPE was within the normal range
for the 10 transfused blood samples (4\ ± J%).
urinary thiamin levels (Figure 6.5, Table 6.5) were
significantly lower prior to the initiation of parenteral or
enteral feeds than at subsequent sampling times. However,
there was no difference found between groups during the study
period. Mean daily thiamin intake exceedl!::d mean daily thiamin
excretion in weeks 1 through J resulting in net positive
balance (Table 6.6). However, it is noteworthy that 27~, 45~,
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Figure 6.3
TABU 6.3
DIETARY THIAMIN (IIIS/kgJd) i J:: SO (n)
Week 1
Week 2
Week 3
PAIl' PAIl'
0.171.:t0.14)" O.487.:t0 .211 ob 0.640±O.175b
(1~) (12) (13)
0.259;10.121" O.476±O.09311o 0.848±O.104e
(17) (3) (6)
O. 271:10.0~3" 0.520tO.170b 0.653±O.306b
(15) (4) (3)
!iellns shllring the same letters in a row at any time periods
slr.nlficantly dlffercnt (p < 0.05).
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TABLE 6.4
ERYTHROCYTE TlANSKETOLAS£ AC1'IVITY (TI'P£ X) i .1 SD (n)
PAR'
S.'IlI!llne ].14- ).11- 2+2-
(il) (14) iil>
Week I I±Z" 1.1]- 2+2-
(12) (10) (9)
Week 2 2!3' Z±4- 2±3'
(7) (6) (5)
Week 3 2!2 I±l
(7) (2)
Means sharing <h. S;IIllIe letters in .cow at any dille periods
sl&nlf!c.1ntly dH£erent (p < 0,05).
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TABLE 6.4a
TRANSKET01.l\SE ACTIVITY
(mg of pentose/II1L helrlolysate!h) X ± SD (n)
Baseline
Week 1
Week 2
Week 3
ENT PAR2 PAR)
3.46±0.64" 2.90±0.3Sb 3.06tO. 49 "b
(13) (If.) (11)
3.35±0.50" 3.00±0.29· 3.15±0.23-
(12) (5) (5)
3.28±0.42· 2.84±0.I.2· 3.46±0.OS"
(7) (3) (3)
3.51±0.51 3.38
(6) (1)
Means sharing the sam", lotters in a rolol lit any tlme poriods nre not siBlllflcnlltly
difforent (p < 0.05).
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URINARY THIAMIN vs TIME
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Figure 6.5
TABLE 6.5
URINARY THIAMIN (lI1gjd) i ± SD (n)
Baseline....
Week 1
Week 2
Week 3
pm PAR'
0.095±0.094· 0.065.10.072· 0.035.10.052'
(7) (8) (7)
0.210±0.1l7· 0.269.10 .184- 0.230.10 . 18 7"
(13) (12) (12)
0.243±0.17S" 0.232.10.19)" 0.))).1°.07/,'
(11) (6) (5)
0.27S±0.17S" 0.315.10.060" 0.)/.2:10.258'
(8) (2) (3)
*A significanL d1fference was observed between baseline values and levels
at subsequent weeks for all 3 groups (p < 0.05).
Means sharing the same letters In a row at any tim!! periods .ore lIot
significantly dl.fCarant (p < 0.05).
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TABLE 6.'
THIAMIN BALANCE f ± SO (n)
Group lnl:lkc Output IIntake Net Retention
me.lkg/d 1JIg/kgjd Excreted mg/kg/d
ENT
week I 0.198±0.147 0.175±0.095 88 0.023±0.149
(It)
week 2 0.268±0.124 0.188±0.136 10 0.080±0.177
(11)
week) 0. 268i.0 ,073 O.202±0.1J7
"
0.067±0.149
(11)
PAR'
week 1 0.485±0.222 O.249.±O.160 SO 0.236±0.314
(11)
week 2 0.48:l.±O.101 0.222±0.177
"
0.26110.199
(6)
week 3 0.55010.195 0.275±0.O96 SO 0.275±0.136
(2)
PAR3
week 1 0.658±0.791 0.1l0±0.053 17 0.5"9±0.806
(0)
w('t>k 2 0.858.±O.079 0.342±0.070
"
0.516±0.107
(4)
\.;c.·k 3 0.495±0.191 0.343±0.258
"
0.152±0.053
(3)
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and 33\ of the ENT, PAR2, and PAR3 infants respectively were
in negative thiamin balance in week 1 and by week 2 the
proportions were 27\, 17\, and 0\. There was no correlation
found between dietary intake and urinary excretion for all the
groups at any time period.
6.4 RI80FLJl"VIN
Dietary ribO!laVin, erthrocyte glutathione reductase
(EGR) activit}', and urinary output for the three groups are
shown in figures 6.6, 6.7, and 6.8, respectively, and in
Tables 6.7, 6.8, and 6.9. Two millilitres of MVr-Pediatric
supplied. 56 mg of riboflavin daily whereas 3 mL supplied. 84
mg. Figure 6.6 illustrates the actual calculated riboflavin
intake for each group. Since not all the prepared feedings
were infused into the infants receiving TPN, there was no
significant difference between the levels of riboflavin
provided to the 3 study groups.
The EGR activity was within the normal range for all
groups at each ti_e period. However, the fGR activity
differed significantly between the PAR3 and PAR2 groups at
week 2 (F.i.gure 6.7, Table 6.8). The EGR activity for 10
samples of transfused blood was within the normal range (1.04
± .15).
urinary ribo!lav in output (Figure 6.8, Table 6.9)
followed the same trend as was seen with urinary thiamin
concentrations. The riboflavin levels at baseline lJithin each
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TABU 6.1
DIETARY I.JBOFUVIN (_&!kg/d) i ± SD (n)
PAR2 PAR'
Week 1 0.J68;:O.263" O.427±0.191' O. ~61±0.6~6"
(16) (13) (13)
Week 2 0.617;:0.2.64" 0.471::0.114' 0.12liO.O!1'
(Hi) (1) (1)
Veek3 O.681;t0.16S' O.4S8±0.lto3' O.626.±O.301,·
(15) (4) (4)
Means sharing the sallie letters in a ro... at tiny time perlolJ
significantly dIfferent (p < 0.05).
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EGR ACTIVITY vs TIME
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TABLE 6.S
EGR AGTIVITY (AG) X ± SD (n)
PAR' PAR'
Raseline 1.01±0.13- 1.0610.13" 1.0('10.1$"
(13) (12) (13)
Week 1 1.04±O.07- 1.03±0.01" l.OO±0.O6"
(15) (9) (11)
Week 2 1.02±O.09-b a.9Rio. 07b 1.1110.10"
(4) (6) (6)
Week , O.99±0.OS- 1.00±0.01" l.OOtO.Ol"
(12) (2) (6)
Heans sharing 'h. Sl\IlU~ letters 1n . .ny timE! period
significantly different (p < 0.05).
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TABLE 6.9
URINARY RIBOFLAVIN (mg/d) i ± SD (n)
PAR'
Raseline* O.lOI±O.US- 0.067±O.078' O.OSS±.O.Oll?"
(7) (11) (9)
Week 1 0.387±0.262" 0.306±0.243" 0.299±O.176"
05) (9) (11)
Week 2 0.344±O.21S" O.299:!;O.151· O. 357:!;O. IllS-
(13) (5) (3)
Week 3 0.2S9±0.165 0.464 0.197±0.117
(1) (1) (3)
*A significant dlfferenee ....as observed between baseline values alii] lcvl']s
at subsequent weeks for all 3 groups (p < O.O~).
Means sharing the salllCl lettets i.n II ro.... lit any tim£! period IIr" IInl
significantly different (p < 0.05).
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TABU: 6.10
RIBOFUVIN BAUNCE X ± SO (n)
Group Intilke Output XIntake Net Retention
me/kg/d IIIg/kg/d Excreted mg/kg/d
f.NT
we(Jk 1 0.368±0.273 0.307±0.184 ,,- 0.05S±0.288
(13)
week 2 0.666±0.212 0. 24610.151 37 0.420±0.224
(13)
week 3 0.65410.180 0.17310.116 26 0.48610.223
(11)
PAR2
week 1 0.370±0.20S 0.265±0.192 72 0.078±0.299
(6)
w\Jek 2 0.SOO±0.124 0.307±0.l94 61 0.192±0.204
(S)
week 3 0.490 0.465
(1)
PAID
week 1 0.615±0.704 0.346±0.241
"
0. 269±0. 660
(11)
w('ck 2 0.7lJ..!,0.106 0.408±O.O80 57 O. 304±0. 164
(3)
w<,ck3 0.626±0.30/i 0.19610.105 31 O.431±O.21,,3
(3)
*Tlwre is " signifiCllnt difference between the net retention in ,-,eeks i
ilnd 2 and weeks 1 .1nd 3 for the ENT group (p < 0.05).
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group were significantly lower than after the initiation of
enteral and parenteral feeds. No difference was observed
between the 3 groups at any time period. A comparison of
intake to output is illustrated in Table 6.10. Mean daily
intakes exceeded mean daily excretions reSUlting in net
positive balance. Even so, 39%, 38\, and 31% of the ENT,
PAR2, and PAR3 groups respectively were in negative riboflavin
balance in the first week. By the second week, 17% of the
PAR2 group were still in negative riboflavin balance but the
ENT and PAR3 infants were all in positive balance. '1'hcre was
no correlation found between dietary intake and urinary
excretion for all the groups except at week 3.
6.5 FOLATE
Data on the tabulated folate intake of infants are
presented in figure 6.9 and Table 6.11. The PAR3 infants
received significantly more folate than the infants in either
the PAR2 or ENT groups in the second week.
A difference was observed in plasma folate between the
PARJ group and both the PAR2 and ENT groups at baseline and
~leek 1 and only between PAR3 and PAR2 infants at week. 2
(Figure 6.10, Table 6.13). A time effect was found between
week 2 values and those measured at baseline and at week 1 for
all study groups. There was no significant difference in RBC
folate concentrations between the 3 groups throughout the
study or within groups over time (Figure 6.11, Table 6.14).
113
ol
o
o
v
"
(»
'"0 0 0
I I I
~DfJ
"1l"1l'"
»»z
:U:U--<
I I
v-'"~~
114
o
r'l
-1
»
:;0
-<
'l
o
r
»
-1
r'l
<
(J)
-1
;:;:
r'l
TASLE 6.11
OIETARY FOUTE (pg/kS/d) i" t SO (n)
EN!
lJeek 1 24±lS'
(IS)
lJeek 2 38.t16"
(17)
lJeek 3 44.t16·
(17)
Means sharing the smile letters 1n
significantly different (p < O.OS).
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PAi2 PAR3
41±lS" 5S~6S·
(12) (D)
4118' 71110h
(7) (6)
3818' 571?7·
(4) (3)
at any til.c period
TABLE 6.12
DIETARY FOLATE FROM TPN SOLUTION AT TIKE 0 VS DIETARY FOLATE FROM TPN
SOLUTION AT TIME 210 FOR TilE PARENTERAL CROUPS. it ± SO.
PAR2 PAR]
Tim" 0
we"k 1 1I1j;18 55±65
week 2 1I1j;8 7l±9
week J J8±8 57±27
Time 2(,
IIc"k 1 3l.±111 1I1:±A8
wc"k 2 3lj;6 511±7
w(,l'k J 29±6 42±21
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PLJl'sI'viA FO LATE \is TI tvl E
c:JEr'if
=PAR-2mL
Q2l PAR-3mL
10 I l':J!plO! 1\11 I JKl! b""I'K)! _n __ j
Baseline Week 1 Week 2 ..
I)eons shoring the some leUe,s 01 any time period ore fl,,\ significantly different ( p ( 0.05 )
• "~;9,,,ficon' diHerence l)elwet''' week 2 ond the other time Pf"ioos wos Gt.se.ved ..,'''in 9""'~'~ ( p \ 005 l
figu re610
1ABLt:6.13
PUr.SKA FOU'rE (ngjmL) X 1 SD (n)
'AR2 PAR'
ll.1seJlne 16±J' lJ±S" 24±7b
"l (10) (9)
WoekI 19±9' 18±4" 32:!;15b
(11) (10) (12)
Veek 2* 22:t12·b 16±4' 30±l6b
(1) (4) (6)
Week 3 20±12 15 28±21
(8) ") (2)
Means shllring the same letters in a rov at lilly time pcriod ate not
fi{tnificantly different (p < 0,05).
*A significant difference between vee\: 2 values and the values at the
other tIme periods vas observed vI thin groups (p < 0.05).
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Figure 6.1 1
TABLE 6.14
RBe FOUTE (ng/mL) X ± SD (n)
'NT ,...., ,....,
Baseline i,Ji,±231" 639±67S" 462±17S"
(1J) (14) (11)
\.leek 1 S2S±S41" 487±474" 772±705"
(13) (12) (15)
WN·k ~. 1139±266" S32±1l63" 1116±196·
(1J) (" (6)
Week) SOl±3S9" 9117±SJ9" 404±33"
(9) (2) (2)
Hellos sh<lring 'h. s:lllIe letters In a any time period
signlficlIntly different (p < 0.05).
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TABLE 6.U
URINARY FOLATE (ug/d) if:!: SD (n)
ENT PAR2 PAR]
lIaseline 1. 35±1.S2 l.O3±O.73 0.53
(2) (4) (1)
Week 1 2.64±O.27 1.56±0.81 1.32±0.54
(3) (7) (3)
Yeek 2 2.65.±1.67 1.21±0.57 1.37
(5) (3) (1)
Week) 2.65.t2.04 1.45
(2) (1)
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Most infants fell within the normal range for plasma (2-45
ng/mL) (Herbert, 1987a) and RBe folate (>110 ng/mL)
concentrations (Becton Dickinson, 1982). Transfused blood
samples were analyzed for RBe folate and the mean value was
134 ± 50 ng/mL.
The radioassay procedure used to determine plasma and RBC
folate levels could also be used to measure urinary folate
concentrations. Figures 6.12 and 6.13 shoW the results of
urine samples from 3 infants and 3 adults using the method of
standard additions. urinary folate output (Table 6.15)
appears to follow a similar pattern as seen with thiamin and
riboflavin. The baseline levels were lower than levels
measured at SUbsequent weeks. These values are a fraction of
the infants' intake and it is evident that all infants are in
positive folate balance. (Unfortunately, these samples
represented a small proportion of the study group since all
but 56 of the urine samples were destroyed due to freezer
breakdown) .
6 • 6 VITAMIN Bj2
Figure 6.14 and Table 6.16 depict dietary vitamin BI~.
intakes. A significant difference in intakes was observed
between the ENT and both parenteral groups in weeks 2 and 3.
However, there was no difference in intakes between the 2
parenteral groups. Ideally the PAR2 group was to receive 0.4
/i9/d whereas the PAR3 group was to receive 0.6 IJg/d but these
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TABLE 6.16
DIETARY VITAMIN Bu (pg/kg/d) X ;t SO (n)
ENT PAR' PAR)
Week 1 0.321;t0.22S· 0.20710.095"
(15) (12)
Yeek 2 0.S48±0.238" 0.219±0.0381>
(17) (7)
\leek 3 0.578±0.110· 0.<!38iO.0781>
(17) (4)
Means sharing the same letters in a
significantly differenr (p < 0.05).
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(13)
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(6)
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TA.8LE 6.11
PLASMA VITAMIN Bl~ (pg/lIIL) "i 1 51) (n)
ENT PAR' PAR'
Baseline 61S±339" 576±309" 791±36S"
ell) (12) (11)
\,leek 1 SH±287" 841±40Sb 924±4241>
(15) (13) (12)
\,leek 2 530...238" 72S±IJ7ob 999±428h
(11) (7) (7)
\,leek) 631±311" 830114" 1217±1022"
(11) (') (3)
Means sharing the same letters in a rOIJ at any time period
significantly different. (p < 0.05).
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infants did not receive their allotted amounts every day
because of their medical treatment.
There was no signif icant diffet"ence found in plasma
vitamin BIz concentratirms within groups ove:- time (Figure
6.15, Table 6.17). A differer,ce was observed between the ENT
group and both the PAR2 and PAR3 groups at week 1 and between
the ENT and PAR) groups at week. 2. Most of the plasma vitamin
BIZ values were within the normal range of 200-900 pg/mL
(Herbert, 1987b). However, 41% of the PARJ group's vitamin
Bll values in the plasma were greater than 900 pg/mL.
Urinary vitamin B12 output could not be detected using the
radioassay procedure. Furthermore, urinary methy1malonic acid
was not detected in 10 of the 12 samples and only traces were
found in the other two samples indicating that there was
adequate vitamin B1.2'
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CHAPTER 7.0 DISCUSSION
7. 1 :INTRODOCT:ION
The aim of this investigation was to assess the
nutritional adequacy of 2 different levels of thiaain,
riboflavin, folate and vitamin BI2 infusions in LBW infants
receiving parenteral nutrition. Large doses of these vitamins
may be dangerouu to LBW infants due to immature renal function
and perhaps impaired urinary excretion, although toxicity froll
water soluble vitamins is rare (Aldaheff et aI, 1984).
In Canada the manufacturer of MVI-Pediatric recommends
that 651; of the amount given to full term infants be givlm to
infants weighing less than 3000 grams. This recommendation
does not differentiate doses for infants who are significantly
less than 3000 g at birth so the question of whether or not
3 mL of this vitamin supplemc>nt may be excessive for very low
birthweight infants «1500 birthweight) requires
examination. Interestingly, this is not entirely the
situation in the U.S. From the results of Hoore's stUdy
(1986) and the concern of vitamin E toxicity resulting in
neonatal death, the FDA issued the stntcr.u:,r.t that 30\ of a
vial of MVI-Pediatric should be used for infants weighing less
than 1000 9 (Greene, 1988). This recommendation has appeared
in the package insert of the U.S. manufactured MVI-Pediatric
since 1985. Even so, 65' of the vial is still the suggested
dose for infants weighing more than 1000 g. The
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appropriat':!ness and safety of providing 30% of a vial of MVI-
Pediatric to extremely LBW infants has not been assessed for
most of the vitamins. However, Phillips and coworkers (1987)
did evaluate the adequacy of 30\ and 65% of a vial of this
multivitamin formulation for infants weighing less than 1000
9 for vitamin E status. They found that vitamin E sUfficiency
was not: maintainod in all infants receiving 30% of a vial
daily. This dose may also have the potential to produce a
deficiency of other vitamins. The new guidelines issued by
the American society of Clinical Nutrition in November 1988
are more consistent with using 40% of a un' ':-dose vial for
most vitamins inclUding folate and vitamin ,Bjl' More
importantly, the recommendations for water soluble vitamins
for LBW infants receiving TPN have been revised to coincide
more closely with the doses for term infants on a body-weight
bilsis.
7.2 VITAMIN CONCENTMTION8 :IN THE TPH ADMIXTURE AND HVr-
PEDIATRIC
MVI-Pediatric was mixed with the parenteral solution
during the TPN mixture preparation. The infusion of the
parenteral solution into the infant usually started 4-6 hours
after the end of preparation. The concentration of thiamin,
folate, and vitamin Bu were determined in the vitamin solution
and in the TPN admixture which was exposed to normal
conditions in the ,Taneway Child Health Centre's Neonatal unit
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during a 30 hour period (Table 6.2).
Unfortunately, the concentration of riboflavin could not
be measured in the TPN solution since no assay technique was
available for measuring riboflavin 5-phosphate, the form of
riboflavin added to MVI-Pediatric. The apoprotein in the
fluorometric procedure used in determining urinary riboflavin
binds free riboflavin and only loosely binds to the phosphate
form (Rhodes et aI, 1959). It would be important to measure
the riboflavin in the TPN solutions administered at the
Janeway Child Health Centre because they are not protected
from light. Riboflavin has been found to be inactivated by
light especially by the high-intensity light used for
phototherapy (Smith et aI, 1988). Chen et al (1983) observed
that after 8 hours of indirect sunlight, the riboflavin 5-
phosphate in a TPN admixture was reduced by 50%. However,
despite the high rate of photodegradation expected from TPN
solutions normally exposed to light, riboflavin deficiency has
not been described in children maintained TPN.
Consequently, due to the unavailability of an acceptable
assay, the riboflavin intakes were calculated using data from
the product monograph and assuming no degradation over time.
Thiamin instabill ty in TPN has been observed in cther
studies (Scheiner et aI, 1981; Smith et aI, 1988). Thiamin
losses were attributed to the bisulfite content of the amino
acids used and to pH. Significant losses of thiamin were
noted at bisulfite concentrations of 3 mEqjL and higher (smith
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et al, 1988). Thiamin levels decreased as bisulfite
concentration increased at pH 5.5 bu·'" at higher pH, thiamin
levels were unchanged. Scheiner et a1 (1981) observed that
the greatest thiamin losses occurred in mixtures of pH 6.5.
In the present study, thiamin remained stable over time but
38% more thiamin was detected in the TPN admixture than what
was listed in the p:':"oduct monograph of MVI-Pediatric for
rea lions that are unclear. As well, 35\ more thiamin was
measured in the mUltivitamin formUlation, itself. Others have
not reported similar findings. However, using a similar
analytical technique, Smith et a1 (1988) measured 39% less
thiamin than expected at the start of their study (time 0) but
did not give an explanation for this discrepancy.
The concentration of folate measured at time 0 in the TPN
solution and in MVI-Pediatric was the same as the amount
reported to be in the multivitamin preparation. Even so, the
concentration of folate decreased significantly by 25% in the
TPN admixture over the 30 hour period examined. Smith at al
(1988) found no effect of time, temperature, container, amino
acid mixture, phototherapy or the presence of Intralipid on
the levels of folate. Barker and coworkers (1984) studied
the stability of folate in a variety of solutions used for
parenteral nutrition. They found that the stability was
dependent upon the pH. Maintaining a pH greater than 5
ensured that the folate remained in solution. Most soluti.ons
for TPN contain amino acids which are amphoteric and will
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exert a buffering capacity ensuring that the pH rem.ains
between 5 and 6. These researchers stated that providing the
acidity of the solution reuins above pH 5, the folate will
remain in solution.
Barker et al (1984) also found that folate remained
stable in the. presence of riboflavin, thiamin, vitamin c,
pyridoxine and panthothenyl alcohol in four typical
formulations of TPN. However, others (Biamonte et al, 19511
Schniedlin et aI, 1952; Tansey et aI, 1954) have shown that
these vi tallins have caused an acceleration in the rate ot
decomposition ot folate which could account for the
degradation of folate observed in this investigation.
Due to the expense of the radioassay used in the present
study, folate concentration was not lIel!l6ured in the TPN
solutions at other time points. It would be of interest to
determine the rate of folate degradation over the 24 hour
infusion period for a IIOre accurate picture of folate intakes.
There was 33t and 10' less vitamin Bn detected in the TPN
admixture and vial at HVI-Pediatric, respectively, than was
reported to be present in the vitamin preparation. using II
radioimmunoassay procedure, Marinier et al (1989) also
observed 30\ less vitamin Bu than expected in the vitamin
solution they were studying. Even so, they concluded that
they found no substantial loss of any at the vitamins during
preparation, storage, or infusion.
The reduction of vitamin 8 12 detected in the TPN solution
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could be due to the presence of ascorbic acid. Vitamin Bu has
been shown to degrade in the presence of ascorbic acid.
Herbert (1976) observed a destruction of 50-95% of the vitamin
BI2 content of meals by 0.5 9 of vitamin c. He concluded that
substantial destruction of crystlllline vitamin 8 12 is brought
about by large doses of vitamin C when no other substances are
present to protect vitamin Bu. This was the reason why
earlier lIIultivitamin formulations did not include vitamin Bu.
Instead,S ug of the vitamin was administered intramuscularly
on a weekly basis.
7 • 3 THE B1I.LANCE TECHNIQUE
The concept of "nutritional balance" has been used to
determine nutritional status as well as nutrient requirements
(Jeejeebhoy, 1986). As part of the assessment of thiamin and
riboflavin nutriture, intake was compared to output to
determine if the infants were in nutritional balance.
Uowuver, the balance method could not be used to aid in the
interpretation of folate and vitamin Bu for three reasons: (1)
there is a slow turnover rate in the body of both these
vitamins (Krumdieck et aI, 19781 Heysscl et aI, 1964), (2)
only small amounts <Ire excreted in the urine, and (3) a large
majority of folate and vitamin 8 12 is reabsorbed from the bile.
The concept of nutritional balance is one of a "black
box" in which the difference between the input and output is
considered to be the balance. If the difference is positive,
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it is assumed that the nutrient is accumulating in the body
and that the accumulation results in growth and/or functional
maintenance and thus, adequate nutritional status. When
considering a vital'lin, positive balance could indicate that
body "stores" are low (e.g., apoenzymes) and thus the patient
is vi tallin deficient and rapidly attempting to replenish these
stores when the vitamin is provided. In contrast, nutrient
intakes associated with a negative balance indicate inadequacy
(Jeejeebhoy, 1986).
Although the balance method yields valuable information
concerning nutrition and metabolism, there are a number of
limitations and sources of error with this technique. The
fate of the nutrients ingested or infused and their
intermediary metabolism are not established from this
technique. Furthermore, the intake tends to be overestimated
while the output tends to be underestimated. When deal ing
with TPN solutions there may be losses of the nutrient due to
adherence to delivery containers and tUbings or due to
degradation when exposed to varying environmental conditions
which if not accounted for could lead to an overestimation of
intake. Unmeasured losses from the skin (including exfoliated
cells, sweat, hair and nail gro....th), flatus, respiration, and
blood sampling lead to an underestimation of output (Kopple,
1987). For instance; excess amounts of riboflavin are
excreted in the urine but small amounts are also lost in sweat
(Cooperman and Lopez, 1984). In the present study, stool
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samples were not collected and analyzed for vitamins for the
ENT group which could have resulted in a further
underestimation of output. It has been observed that 20-30%
of ingested thiamin was excreted in the feces of rats (Light
at aI, 1938). Due to the limitation of balance studies, other
parameters of nutritional 'lnd metabolic status were used in
association with intake and output data to assess the adequacy
of the four vitamins examined in this investigation.
7.4 'I'HIAMI"N
Ensuring that a LBW infant is receiving appropriate
tlmounts ot thiamin is important since thiamin plays a critical
role in neurological function (Haas, 1988). Even though
toxicity of thiamin is extremely rare, high doses have been
associated with respiratory depression and anaphylaxis
(Aldaheff et aI, 1984). Excess thiamin has been shown to
result in an increase in urinary thiamin output (Sauberlich
at aI, 1974). The J:elationship of thiamin intake to output
in the present stu~y is reported in Table 6.6. The mean net
retention was positive for all 3 groups. It 15 interesting
to note that 88%, 50%, and 17\ of the thiamin intake was
excreted by the ENT, PAR2, and PAR3 groups, respectively,
during the first week. In the second week the ENT infants
excreted 70% of their intake whereas the infants in the PAR2
group excreted 46% and those in the PAR3 group excreted 40%.
The results obtained in the three weeks are extremely
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important since the PAR3 group received significantly more
thiamin than the other 2 groups. As well, the PAR3 infants
who were receiving a parenteral infusion averaging .846 mg
thiamin/kg/d were all in positive balance by week 2.
The large urinary thiamin excretion exhibited by infants
in the 3 study groups could be attributed to a number of
factors. Thiamin excreted in the urine is dependent upon 1)
the amount of thiamin ingested, 2) the amount absorbed in the
intestine, 3) the metabolism of the individual, 4) the
quantity of urine, and 5) the kidney threshold. Benson et
al (1942) studied the urinary thiamin excretion of 22 healthy
children ranging from 4-10 years of age. These researchers
found a variation in thiamin output. The average amount of
thiamin excreted was 27% of the amount ingested. They
observed that some of the children who received a greater
thiamin intake excreted less than others who had a lower
intake. They attributed the variation in output to the
capacity to absorb the vitamin. The varying degree of
absorption was made more apparent when large test doses were
given. In fact, Schultz et al (1938) shOwed that high doses
of thiamin were incompletely absorbed.
In the present study, the proportion of thiamin intake
excreted dramatically decreased in the second week for the ENT
group. Two factors may have influenced this result. Firstly,
thiamin is involved in oxidative reactions involving
carbohydrates. An increase in carbohydrate calories ingested
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and utilized has been shown to result in an increased need for
thiamin (Sauberlich, 1964). Since the ENT group was receiving
more energy by the second week, this could account for the
need to retain more thiamin than previously. Secondly, due
to renal immaturit.y, excretion of thiamin and riboflavin by
the infant could be relatively rapid (Jusko et aI, 1970). The
'ct that the SUbjects' kidneys are not as well developed or
functional in the early stages of life and that approximately
25% of parenterally administered vitamins perfuse the kidney
before the liver and intestine (Hodges and Dempsey, 1986)
could account for the large thiamin output by the PAR2 group
during the first week. The reason for the PAR3 group
excreting ..,,"ly 17% of their intake in the first week is
unclear. The kidney has the ability to favourD.bly adapt to
continuous parenteral infusion compared with intermittent
enteral ingestion of water soluble vitamins (Schanler, 1988).
While the mechanism is still unknown, this could explain why
the two parenteral groups excreted less of their intake than
the ENT group.
There was adequate thiamin provided according to the
'rpPE (Figure 6.4, Table 6.4) as was found by others (Moore et
aI, 1986) for infants rE"ceiving 3 mL of MVI-Pediatric. Normal
'I'PPE values fall within the range of 0-15%. Values at the
higher percentages indicate that the in vitro addition of TPP
was needed for the normal functioning of the enzyme,
transketolase. In the ENT group, 36% of the infants at
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baseline had TPPE values in the range of 7-10\. These values
are normal but could indicate that less ';"'hiamin was available
for normal functioning at birth. However by week I, only one
child had a TPPE of greater than 5\. In the PAR2 group, 2
infants had TPPE valuos of 14' and 26' at baseline but these
high values were reduced to e' by week 1 suggesting thi!lot once
TPN was initiated these infants were receiving adequate
thiamin. High values at baseline may imply loW' stores in
utero or low maternal intake. No abnormal TPPE was observed
in the PAR) group.
In thiamin-deficient people transketolase activity is low
and can usually be increased by added TPP. However, this
increase, or TPP effect, requires the presence of
apotransketolase. In some cases, there appears to be no free
apoenzyme which can react with TPP, so the transketolasc is
low but not increased by TPP. Thus Sauberlich (1967) argues
that "it appears essential that attention be given to both the
T[,~ stimulation effect and the maximum enzyme activity when
transketolase evaluation is considered". In the present
stUdy, no difference was found regarding transketolasc
activity for the 3 groups at weeks 1, 2 or 3 (Table 6.4a)
suggesting adequate levels of the apoenzyme.
TPPE does not distinquish between adequate and/or
excessive intakes. Therefore whole blood thiamin may serve
as a better quantitative measure 0[' thiamin status. The PhR2
group excreted more thiamin than the PAR) group. (It may be
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that blood thiamin concentrations are higher in the PAR3 group
than the PAR2 group.
By the second week, the ENT group received a mean intake
of 0.259 mg/kg/d, the PAR2 group 0.476 mg/kg/d, and the PAR3
group 0.848 mg/kg/d (Figure 6.3, Table 6.3). In another study
(Fritz, 1987 abstract), intravenous intakes of 0.11-0.13
mg/kg/d corrected the erythrocyte transketolase activity tor
2 infants deficient in thiamin. Elevated whole blood thiamin
levels were seen in term infants who received 0.12 mg/kg/d
(Greene et aI, 1988). In light of these studies, Greene et
al (19BB) recommended that LBW infants receiving TPN should
receive -0.35 mg/kg/d of thiamin. Until blood levels are
measured, we cannot comment on the appropriateness of this
suggestion. In the present stUdy, the PAR2 group received the
amount provided by 40," of a vial of MVr-Pediatric. These
infants had adequate tissue function and were in positive
thiamin balance. ThUS, it appears that approximately 0.48
mg/kg/d or less is sufficient for L8W infants receiving TPN.
7 • 5 RIBOFLII.VIN
Phototherapy, the treatment for hyperbilirubinemia, has
reSUlted in riboflavin deficiency in LBW infants receiving
enteral feeds (Sisson, 1987; Bates et aI, 1985; Lucas and
Bates, 1984). Ennever et al (1983a, 1983b) showed that
excessive amounts of riboflavin under phototherapy
illumination resulted in tissue damage in isolated cells.
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ThUs, these authors suggested that caution be exercised when
providing large supplements of this vitamin to neonates
receiving phototherapy. These findings are of particular
concern in the present study because 48% of the infants
underwent phototherapy in their first week of life.
Since. the infants in the parenteral group did not receive
all the prepared TPN', the PAR) infants did not receive
significantly more riboflavin than the other two groups
(Figure 6.6). When examining riboflavin intake to urinary
output in weeks 1 and 2 (Table 6.10), it was observed that
83%, 72%, and 56% of the riboflavin intake was excreted by the
ENT, PAR2, and PAR) infants, respectively, in week l.
Furthermore, 37\, 61%, and 57% of the riboflavin ....as excreted
by the EN'T, PAR2, PAR) infants in the second week. There was
a significant difference between the proportion of intake
excreted for the ENT group at weeks 1 and 2 (p < 0.05).
All 3 groups excreted high percentages of their
riboflavin intake, especially in the first week. When given
in excess of needs, riboflavin is excreted primarily unchanged
in urine. In fact, if body stores are saturated, others have
reported quantitative excretion of intake in the urine of
adults (Selhub and Rosenberg, 1984). Oldham et a1 (l942)
studied the urinary thiamin and riboflavin excretion in two
5 year old children. They observed an increased riboflavin
excretion when the children had upper respiratory infections
and no change in thiamin output. The authors stated that this
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increase in riboflavin excretion was probably related to a
lack of protein deposition and a negative nitrogen balance.
urinary riboflavin excretion has been shown to be closely
related to alterations in nitrogen balance. Sarett et al
(1942, 194)) observed that the urinary riboflavin excretion
of dogs and rats varied inversely with protein intake and
protein deposition. Thus vhen the protein intake vas
decreased, the capacity to retain riboflavin vas lost.
Pollack and Bookman (1951) found that large negative nitrogen
balances precipitated by surgical procedures were associated
with excretion of riboflavin many times that of the quantity
ingested. These authors suggested that any appreciable excess
quantity of riboflavin being excreted in the urine could be
attributed to the breakdovn of flavoproteins. Cayer and Cody
(190\7) reported a 251 increase in riboflavin excretion in
patients vith peptic ulcer and suggested that increased
~xcretion might be attributed to body veight loss with
resultant riboflavin release from tissues.
At the start of the present stUdy most of the infants had
medical problems vhlch may have lead to the large urinary
output observed in ....eek 1. By the second veek, the ENT
group's excretion was lowered by 451 which would be expected
since this group improved cl inically. However, the riboflavin
output only decreased by 19% and 10\ for the PAR2 and PAR)
groups, respectively. These infants continued to have medical
complications which was exemplified by the fact that they were
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still receiving TPN. Nitrogen balance was not assessed in the
present study but it should be considered in future
investigations to determine if there is a correlation bet'.leen
nitrogen balance and riboflavin excretion in urine for LeW
infants.
A functional enzymatic assay was used to determine
riboflavin nutriture in this investigation. According to the
results, the infants in the ENT, PAR2, and PAR3 groups had
adequate riboflavin for normal biochemical functioning (Figure
6.4). Cooperman et al (1973) found that the EGR activity
coefficients of cord blood were approximately 1.00 indicating
that EGR in neonates at birth was saturated with the
riboflavin-containing coenzyme, FAD. Moore et al (1986) had
results similar to those found in this investigation for
infants weighing less than 2500 g receiving 3 mL of MVI-
Pediatric.
EGR activity values greater than 1.20 indicating a
riboflavin deficiency, were observed in I Pl\R2 infant and 1
ENT infant at baseline and 1 ENT infant and 1 PAR3 infant at
week 2. The high activity coefficients at baseline could be
attributed to decreased stores in utero or maternal intake
since these were reduced to normal values once feeds were
initiated. surprisingly, the infants with high activity
coefficients at baseline were not the same infants with high
TPPE's. The 2 infants with high activity coefficients at week
2 did undergo phototherapy in week 1 and the infant in the
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PAR3 group received a blood transfusion the day before blood
was drawn for the vitamin study. Thasa 2 factors could have
contributed to the incraase in EGR activity. For the most
part, the EGR activity coafficients determined in this study
suggest that the infants had adequllte riboflavin but they do
not indicate whether or not excess riboflavin is being
metabolized or if tissue stores are high.
In studying LBW infants, Baeckert and coworkers (1988)
observed that a parenteral riboflavin intake of 0.66 mg/kg/d
resulted in a 20--400 fold elevation in blood riboflavin levels
and an intake of 0.25 mq/kqjd for 2 days resulted in only a
-4 fold increase. These authors postulated that this increase
reflected an excessive intake and a relatively poor renal
clearance of riboflavin. Therefore we suggest that blood
concentrations of riboflavin be measured as well as
determining functional adequacy and urinary excretion levels.
Fritz (1987, abstract) observed 2 infants who received
no riboflavin for 21 days. They both had an EGR activity
coefficient indicative of riboflavin deficiency. The abnormal
activity coefficients were corrected when riboflavin doses of
0.06 and 0.096 mg/kg/d were given to both patients,
respective-Iy, for 2 days. This supports the contention that
currently recommended doses of riboflavin are excessive. This
finding along with the results from the studies by Baeckert
(1988) and Moore (1986) led Greene and coworkers (1988) to
suggest that 0.15 mgjkg/d of riboflavin would be adequate for
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LBW infants receiving TPN. As intakes of these low levels
were not evaluated, comment on the appropriateness of these
recommendations is not possible. However, from the results
of this investigation, we can suggest that approximately 0.45
mg/kg/d of riboflavin or less is adequate for LBW infants
being parenterally fed.
7.6 FOLATE
Since folate is required for growth and
erythropoiesis (Rodriquez, 1980) LBW infants may have a need
for higher supplementation than term infants. There is a
scarcity of data available on the effects of excess folate.
However, Ford et al (1975) suggested that excess folate may
have an adverse affect on the microbial popUlation in the
intestine of infants by increasing the growth of folate-
requiring bacteria. consequently, it may not only be a matter
of folate supplementation but a matter of therapeutically
appropriate dosages which require consideration
investigation.
Little information is available about folate levels in
plasma and red blood cells during and after long term
supplementation with folate in TPN. Determining RBC folate
concentration is the most common index used to assess folate
status. From the reSUlts (Table 6.14), the infants in all J
groups had adequate folate stores. Infants in the present
stUdy had plasma folate concentrations of 19 ± 9 ng/mL, 18 ±
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4 ng/mL, and 32 ± 15 ng/mL for the tNT, PAR2, and PAR) groups,
respectively, in the first week and 22 ± 12 ng/mL, 16 ± 4
ng/lnL, and 30 ± 16 ng/mL in the second (Figure 6.10). The
PAR) infants received significantlY more folate than the other
2 groups in week 2. Surp:r:isingly, the PAR) group's mean
plasma folate level did differ from that of the ENT and PAR2
groups prior to the initiation of feeds and at week 1 but
differed only from the PAR2 group at week 2.
Two infants in the ENT group and 2 in the PAR) group had
high plasma folate values during the course of the study. One
of the infants in the ENT group was switched to TPN by the
second week due to medical complications that could account
for the higher value. The other infant had many problems at
birth including sepsis, hypoglycemia and jaundice.
Furthermore, this child had high plasma vitamin Bl2
concentrations throughout the study. The 2 infants in the
PAR3 group with elevated plasma folate levels also had high
plasma vitamin Bn . Both of these infants had multiple medical
problems, high concentrations of RBC folate and blood
transfusions by week 2. It may be possible that all four
infants had diffiCUlty with the metabolic handling of these
vitamins.
There was no correlation found between dietary folate and
plasma folate for all three groups at any time period. As
well, a comparison of intake to output was tabulated but,
unfortunately, there were too few samples, especially by the
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second week, to be able to determine statistical significance.
Only a small proportion of the intake was excreted in urine,
indicating that most of the folate is probably reabsorbed.
Tamura et al (1980) studied term infan~,:; (3-25 wecks)
receiving breast milk which contained a me·,n folate
concentration of 141 ng/mL. Their daily intake ranged from 14-
25 ug/kg/d. Plasma folate and RBC folate levels ....ere 29 ± 14
ng/IlIL and 429 ± 186 ng/mL, respectively. These values are
similar to those of smith et al (1985) ....ho studied infants
from birth to 6 months. Ek and Magnus (1979) analyzed plasma
and RBC folate in breast fed infants during their first year
of life. Plasma folate values were 13-20 nglmL and RBe folate
values were 264-396 ng/mL. The results from these studies
appear to be consistent with the folate concentrations
determined in the present investigation. More importantly,
Moore et a1 (1986) measured RBC folate in LBW infants
receiving TPN and their results were similar to those observed
in this study.
Ek (1988) suggested that 65 ug/d or -15 ug/kg/d would be
adequate for LBW infants whereas Greene et al (1988)
recommended 56 ug/kg/d for those infants receiving parenteral
feeds. By the second week the PAR2 group was more like the
control group (ENT) than the PAR3 group in the amount of
folate received and the folate concentration measured in
plasma. Therefore, it appears that 40 ug/kq/d, the amount
received intravenously by the PAR2 infants, would be
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sufficient for LBW infants receiving TPN.
1.1 VITI.MIJrf 8 12
vitamin Bll has an important role in folate metabolism for
2 reasons; I} it is a constituent of methylcobalamin, a
cofactor necessary for folate metabolism, and 2) it is
involved in the regeneration of folate for nucleic acid
metabolism (Ellenbogen, 1984: Herbert, 1981b; shinton,
1912). These two factors suggest that vitamin Bll is essential
for the developing infant.
Vitamin BIZ as well as folate lmd vitamin K can be
synthesized by bacteria in the gut. However, antibiotics were
adflinistered to 79' of the infants in this study as part of
their medical treatment and more than likely, interfered with
the microbial production of these vitamins. Therefore, it is
imperative that these infants receive vitamin Bn either
intravenously or intramuscularly.
since there is no difference between the amount of
vitamin Bu the PAR2 and PARJ infants received, the results of
both groups can only be compared to the data obtained for the
ENT group. The ENT group received significantly more vitamin
BIZ than the PAR2 and PARJ groups in week 2. Surprisingly, the
PAR) group had significantly higher plasma vitamin Ba. values
than the ENT infants in weeks 1 and 2. In fact, 41% of thQ
samples from the PAR) group had levels greater than 900 pg/mL
whereas only l5t of the PAR2 and 8t of the ENT samples were
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above this value. Moore et al (1986) obtained plasma vitamin
Bn levels in the range of 1000-2900 pg/mL 1n their group of
18 LBW infants receiving J mL of MVI-Pediatric. These
researchers observed no significant difference over time which
is consistent with the results of this study. Furthermore,
there was no correlation found between dietary vitamin BIZ and
plasma vitamin Bn for all three groups at any time period.
No vitamin Bn was detected in the urine that was analyzed
and only traces of urinary methylmalonic acid were measured
suggesting no deficiency. It is true that a large percentaqe
of vitamin Bla is absorbed; however, it has been observed that
following intravenous administration 50-90% of the dose is
excreted in the urine within 48 hours in adults (Ellenbogen,
1984) . Either all the vitamin Bn is reabsorbed due to
increased need or the negligible output is the result of poor
:renal clearance leading to the high blood levels seen in the
PARJ infants.
Since a marked elevation of plasma vitamin BIZ was
observed with infants receiVing 0.6 ug vitamin Bn/kg/d
intravenously (Moore et aI, 1986), Greene and coworkers (1968)
suggested that 0.4 ug/kg/d would be adequate for LBW infants
being parenterally fed. This amount is consistent with 40%
of the amount of vitamin BIZ recommended for full term infants
receiving TPN and thus, the amount given to infants receiving
2 mL of MVI-Pediatric. Because the majority of plasma vitamin
BIZ values fell within the normal range of 200-900 pg/mL for
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the PAR2 group and the fact that the mean plasma values did
not differ from that of the control group, it appears that
0.20-0.25 ug/kg/d is sufficient for LBW infants receiving TPN.
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Chapter 8.0 CONCLUSION
From the results of this study, it appears that supplying
intravenously fed LBW infants 1.5-1.6 mL of MVI-Pediatric (the
actual mean amount given to the PAR2 infants [Table 6.la]) is
sufficient to maintain normal biochemical functioning of
thiamin, riboflavin, folate and vitamin Bu' However, if the
infants had received their full complement of the vitamin
formulation, the amount of riboflavin, folate, and vitamin BI~
may have then been excessive. We can further suggest that
providing approximately 0.48 mg/kg/d of thiamin, 0.45 mg/kg/d
of riboflavin, 40 /.'9/k9/d of folate and 0.20 - 0.25 /.'g/kg/d
of vitamin Bu would be adequate for LBW infants receiving TPN.
LBW infants are difficult to study because of their
vulnerability and need for constant intensive care. Even so,
the need to determine their nutrient requirements is
imperative. This investigation has provided the framework for
future research to be carried out with this population group.
The outcome of this study along with the many problems
experienced with the experimental design has led to insight
and sU9ryestions that will benefit further investigative \/ork
in this area:
1) Infants may not receive their total TPN infusion. This
i~ an important observation for future balance studies.
If possible, these infants should receive the full
complement of the nutrient being examined.
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2) Developing a statistical method for dealing with missing
values is essential for this kind of study that precludes
the use of the repeated measures of analysis design.
J) Blood and fecal levels as well as functional enzymatic
assays and urinary excretion should be determined for a
more definitive interpretation of thiamin and riboflavin
nutriture.
1\) using a dose response curve design would allow for a more
accurate determination of vitamin requirements.
5) Actual v Hamin concentrations in TPN solutions and the
vitamin formulation should be measured to determine the
accuracy of the product lIonoqraph and to observe possible
degradation over the entire infusion period.
G) The unit dose of any of the vitalllins should be
recommended on a body weight basis which is consistent
with the current trend for other nutrient requirements
for LBW infants.
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l\PPENDIX A
water Soluble vitamin Status of LOW Birthweight Infants
Water soluble vitamins are essential for life and are
present in small amounts in the body and food. However, we
do not know exactly what levels are required by newborn babies
who are being totally fed by liquid into a vein. Although
y.1ur baby was not fed by intravenous infusion, we are in need
of orally fed low birthweight infants with whom to compare
intravenously fed babies.
A 1 ml blood sample taken once a week for a period of
four weeks. These samples will be taken at the same time
as routine collection.
At different times during the study, collections of urine
which would normally be discarded. These collections
will be tak.an during a 24 hour period which, in our
experience, rarely causes irritation to the child.
There will be no known risk to your baby in the study.
Although there will not be any direct benefit to your child
from this study, the knOWledge gained will be valuable in
assisting us in our understanding of vitamin requirements
during intravenous feeding for these babies.
You may decide not to participate or may withdraw from
the study at any time without affecting your normal treatment.
I, agree to allow my child _
to take part in the study water Soluble Vitamin Status of Low
Birthweight Infants. I also acknOWledge tha~. the study has
been made as clear to me as possible by Dr.
or his research assistant. Any questions have been answered
to my :;atisfaction.
signed (Patient)
_________ (Doctor or Research Assistant)
(Witness)
Date
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APPENDIX B
Water Soluble Vitamin status of Low Birthweight Infants
Water soluble vitamins are essential for life and arc
present in small amounts in the body and food. no....ever, we
do not know exactly what levels are required by newborn babies
who are being totally fed by liquid into a vein. If you agree
to allow your baby to participate, we will need:
1. A 1 ml blood sample taken once a week for a period of
four weeks. These samples will be taken at the same time
as routine collection.
2. At different times during the study, collections of urine
which would normally be discarded. These collections
will be taken during a 24 hour period Which, in our
experience, rarely causes irritation to the child.
There will !"-'i! no known risk to your baby in the study.
Al though there will not be any direct benefit to your child
from this study, the knowledge gained will be valuable in
assisting us in our understanding of vitamin requirements
during intravenous feeding for these babies.
You may decide not to participate or may withdraw from
the stUdy at any time without affecting your normal treatment.
I, agree to allow my child __
to take part in the study Water Soluble vitamin status of Low
Birthweight Infants. I also acknowledge that the study has
been made as clear to me as possible by Dr.
or his research assistant. Any questions have been answered
to my satisfaction.
Signed
Date
________ (padent)
_________ (Doctor or Research Assistant)
_________ (Witness)
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APPENDIX C
"METABOLIC BED"
APPENDIX D
"SWEDISH NITEX MESH"
a 2
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APPENDIX E
ERYTHROCYTE TRANSKETOLASE ACTIVITY ASSAY
SAMPLE PREPARATION
The samples were prepared by using 200 ~L of red blood
cells diluted 1:1 with distilled water.
REAGEN'1' PREPAR1I.TION
(i) Buffer: 0.9\ NaCl
1.15\ KCl
1.75% K2HP04
3.82% MgS04 '7H20
3.13 mL
80.50 mL
15.60 mL
0.77 mL
1 N Hel was used to bring the pH to 7.4
(ii) TPP
a) stock solution: 25 rng Cocarboxylase (TPP): 25 mL
buffer
b) working solution: 1 rnL stock solution: 16 mL buff.er
(iii) 5% TCA
(iv) Pentose standard Solution
a) stock solution: 1 mg D-ribose: 1 mL distilled water
b) working solution: 1 mL stock solution: 100 mL
distilled water (10 ~g/mL)
(v) Orcinol reagent
a) "JO%" HCl: J parts Hel cone. to 1 part distilled
water
b) ~. i6~r~i~~~lJ'H20~ to 50 mL water
c) dilute b) to 1000 mL ....ith "JO%" lIel
(vi) SUbstrate: 0.084 9 Ribose-5-phosphate disodium salt to
7 mL distilled water. Add buffer to 6.8 mL substlatc to
obtain a volume of 10 mL.
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C~LCIJLlr.TION8
The amount of pentose utilized per mL hemolysate per hour
is calculated following the steps outlined below.
(i) Dilution Factor (OF)
OF .. -7- x¥- x:ic - 180
-amount of hemolysate
btotal volume
c llL filtrate used
(ii) Average absorbance/~g pentose standard eSP)
SP .. (00,/5 + 0°10/10) + 2
(iil) KP = DF/SP
(iv) 2R + 0 '" amount of pentose originally present in the
group of tubes prior to incubation
(v) TP I = (2R + 0 - A) x KP '" ~g pentose used/mL hemolysate/h
without TPP
(v1) TPz - (2R ~ 0 - B) x KP .. Jl9 pentose used/mL hemolysate/h
with TPP
(v) TPPE' '" TPz - TPi/TPI X 100
For contents of tubes A. B, Rand 0 refer to Tables 5.1 and
5.2.
A - absorbance without TPP
B .. absorbance with TPP
o - amount. Qf pantose endogenous to sample
R = this tube contains substrate to determine the amount of
pcntose utilized
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APPENDIX F
ERYTHROCYTE GLUTATHIONE REDUCTASE ACTIVITY ASSAY
SAMPLE PREPARATION
The samples were prepared by using 50 IJL red blood cells
diluted with 950 I-'L distilled water.
REAGENT PREPARATION
All reagents except the buffer were prepared the day of
the assay and kept on ice.
(i) 0.27 mM FAD: 0.0022 g/10 mL distilled water
(ii) 1.9 mM NAOPH: 0.016 g/lO mL n sodium bicarbonate
solution
(iii) 7.4 mM GSSG: 0.0452 g/10 mL distilled water/O.l mL 1
N NaOH
(iv) 80 mM EDTA (tetrasodium salt): 0.1521 g/5 mL distilled
water
(v) 0.1 M potassium phosphate buffer (pH brought up to 7."
with SN NaOH
CALCULATIONS
ACTIVITY COEFFICIENT (AC) '" }ll:DUCTION OF ABSORBANCE WITH FAp
~EDUCTION OF ABSORBANCE WITIIOUT FAD
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APPENDIX G
RADIOASSAY PROCEDURE-FOLATE AND VITAMIN B'I~ DETERMINATION
SAMPLE PREPARATION
(i) PLASMA FOLATE AND VITAMIN BIZ: The samples were diluted
to a 1:1 ratio with distilled water.
(ii) RBe FOLATE: Fifty microlitres (50 ItL) of whole blood was
diluted with 1 mL of freshly prepared C.2%: ascorbic acid
solution (w/v) (1:21 dilution). The hematocrit is
necessary for the determination of RBC folate.
CALCULATIONS
1) PLASMA FOLATE AND VITAMIN Bu
Average the counts found for the blank tubes (3 & 4)
and subtract this value from all other tubes to obtain
corrected counts
Average the total counts (1 & 2) to obtain the Total
count per assay
Trace Binding, 80 (should be > 35')
Bo = average corrected cou~ x 100
Total Count (1 & 2)
1; Trace Binding = corrected count (samples) x 100
average corrected counts (5 & 6)
Plot standard curve on 109it-log paper (Appendix H) .
\; Trace Binding vs pg/mL vitamin Bu or ng/mL folate.
Concentration of vitamin BIZ or folate in samples can
be obtained from the standard curve and mUltiplied by
the dilution factor.
2) RBC FOLATE
Calculate \; Trace ~inding for the hemolysate
Obtain the concentration of folate from the standard
curve
ng/mL of packed red cells = (nq/mL hemolysatel x 21
\; hematocrit/lOa
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1r.PPENDIX I
URINARY THIAMIN ASSAY (THIOCHROME PROCEDURE)
REAGENT PREPARATION
The reagents were prepared -che day of the -a:;:;ay.
(i) 1 N NaOH
(i i) Isobutanol
(iii) oxidizing Reagent: 2 parts 2% potassium ferricyanide
to 4 parts 40' NaOH
(i v) Uenezenesulphonyl chloride (aSC)
(v) 3\ H20 2
(vi) Standard thiamin solution (0.2 Jl9/mL)
CALCULATIONS
~g thiamin/mL urine .. Tube B - Tube C x Q....!
Tube A - Tube B 2
Tube a - Tube C represents the fluorescence due to
thiochrome produced from thiamin in urine.
Tube A - Tube B represents the fluorescence due to the
thiochrome produced from the added thiamin
standard.
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APPENDIX J
URINARY RIBOFLAVIN ASSAY (FLUOROHETRIC APOPROTEIfoI TITRATION)
SAMPLE PREPARATION
Dilute control urine 1:10 or 1:100 with TRIS and sUbjects
urine 1: 200. Standards were prepared with TRIS and ranged
from 0 -40 ng/mL.
rlEAGENT PREPARATION
(i) 0.05 M TRIS, pH 7.S (concentrated Hel was used to obtilin
desired pH)
(ii) Standard riboflavin solution
a) Stock solution: Dissolve 19 mg of riboflavin up to
500 mL with distilled water which contains 1 mL \leI
(0.038 mg/mt)
b) working solution: Dilute 1 mL stock solution up to
200 mL with distilled wllter (190 ng/mt)
(iii) Apoprotein: Dissolve 1 mg apoprotein with 1 mL O.O~ M
TRIS.
Oilute 1:4 with TRIS and keep on ice.
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APPENDIX It
STATISTICAL FORMU~ (DESIGNED BY DR. SUTP.ADMR, DEPARTMENT OF
KATHEMJ,TICS AND STATISTICS, HUN).
EXPERIMENTAL DESIGN
T, T, T,
U, nil'
'"
n 21 , )(21 nJI , X31 N.,
U,
"12' X\2 "22' X 22 nn, Xn N.,
U,
"IJl XI] "n, X23 "31' >en N.,
N" N" N"
where T: treatment
U.. time period
NT' ,"otal sample for treatment
N~ = total sample at each time period
n = sample size per cell
x = mean per cell
A) To determine if there is a treatment effect between
groups, calculate a 5% confidence interval using the
following procedure:
Example: for T] - T:
(T l - T:) - 1.96 J v(f] - Td<T] - T 2<('T 1 - 102 ) + 1.96 J V(T: - T2)
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where; T: .. nllgll.""±""'OI~u--±-.DU&U_
Nn
102 .. D..21&ZI....±.......nUK:2--±--D.2J&'l_
N"
V(T1 - Tz).. C V~T:) + V(T:J - 2 COY (Til Tz)
·:··.e(~~v_ ~\ -= ~(i\) 1;(~:l
where V(Td "'...Lz tnuallZ + nlZOIZz + nuo u z + 2(nlln1201Z + nllnlJo11Nn
+ n I2n Uo:)),
where 0 (covariance) '" ----l..-! (Xl - x) (YI - y)
it.~-l '0\
itA random sample was obtained for each time period using the
smallest n for treatment and assuming a homoCJenous group
wi thin the cells.
B) To determine if there is a time effect 'Within groups,
calculate a 5\ confidence interval using the following
procedure:
, ,
Example: for U j - I,l'z
(ljl - Vz) - 1.96 jV(Ut - UZ)<U1 - Uz< (U j - Uz) + 1.96 JV(U1 - Vz)
where; U1 "" nll~lI....±.....oU&ZI.....±......nJI:&J1_
No>
U2 '" nliju_±_1l2ili222._!h~J2 __
No>
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... 2 ("ll"ZI012 + "\I"lIOI3 -+ "ZI"llOZl) '" 0
VCUd '" -d--r ("\10\/ -+ nZ10Z/ + nnOJ1 2 )
No>
V(l\) :: +r (nIZO I/ + "220222 + ")20)/)
NO,
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